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ABSTRACT 
Protein detection is of great importance in both research and clinical settings. The use of 
proteins as diagnostic markers of disease is a driving force behind the development of advanced 
protein detection techniques. Of particular interest is the development of a detection platform 
which is both highly sensitive and capable of simultaneously quantitating a number of targets, as 
a single biomarker is seldom capable of providing the information necessary to make 
sophisticated diagnostic determinations. The Bailey Group has developed a detection platform 
based on silicon photonic microring resonators which is capable of making sensitive 
measurements of proteins, as well as other biomolecules, in complex matrices. 
The following chapters present the work I have completed towards the development of 
particle-based detection schemes for use on the microring resonator platform. Chapter 2 details 
the initial attempts at detection of a particle-like species, namely Bean pod mottle virus, from the 
complex matrix of minimally-processed leaf extracts. Chapter 3 details the initial developments 
of magnetic-bead based assays for lower limits of detection and extended dynamic range. 
Chapter 4 details the extension of previous magnetic particle detection by incorporating a 
permanent magnet into the chip holder in order to direct magnetic beads towards the surface of 
the sensor, effectively shortening analysis times and further decreasing limits of detection. 
Chapter 5 begins to move away from bead-based assays and discusses studies directly comparing 
bead-based signal enhancement strategies with enzyme-based strategies. Chapter 6 discusses the 
initial developments into a multiplexed biomarker panel for the detection and discrimination of 
liver diseases. Chapter 7 speculates on the future of the methods I have developed and discusses 
where I believe there is room for improvement and further development arising from my work. 
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Finally, there are two appendices which present small studies and initial work which may be a 
valuable reference for future students. 
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Chapter 1 
 
Introduction and background 
 
1.1 MOTIVATION 
Proteins are of great research interest in areas ranging from the basic biological level to 
practical biomedical applications due primarily to the role that they play in mediating biological 
function. As such, they are frequent analytical targets for a range of applications from basic 
functional studies to disease diagnostics and treatments. Inherent in these applications is the need 
for a successful detection platform. An ideal platform would have high sensitivity, low limits of 
detection, a wide dynamic range, low analysis times, multiplexing capabilities, and require little 
operator training. 
Proteins are frequently used as diagnostic markers, especially in the field of cancer 
diagnostics. There are currently fewer than 25 FDA approved cancer biomarkers, including such 
frequently studied proteins as alpha-fetoprotein for hepatocellular carcinoma, CA19-9 for 
pancreatic cancer, CA-125 for ovarian cancer, prostate specific antigen (PSA for prostate cancer, 
and carcinoembryonic antigen for a variety of cancers
1
. Unfortunately, determinations made via 
a single biomarker are often unreliable. Taken as a classic example, PSA fails to fulfill the 
requirements for a good diagnostic
2
. It suffers from high rates of false positive and false negative 
results. This is far from unique when making determinations with a single biomarker. Indeed, it 
is believed that to achieve a truly unambiguous result, a protein-based diagnostic test would need 
to include an array of targets, prompting a great deal of research in this field
3
. The varied 
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abundancies and physical characteristics across possible biochemical targets present a host of 
challenges to the realization of an ideal protein detection platform. The wide range of protein 
concentrations found in biological samples, for instance from pg/mL to 10s of mg/mL in human 
blood, make it difficult to design a detection platform with sufficient dynamic range to 
simultaneously quantify proteins whose concentrations lie at opposite ends of this spectrum
4
. 
The availability of well-functioning capture agents places a restriction on the targets it is possible 
to interrogate using most common analytical methods. Additionally, cross-reactivity between 
proteins, both in a sample and on-sensor, make implementing biological controls a necessity on 
almost all platforms. Though many detection methodologies are able to overcome some or many 
of these obstacles, none are able to address all of them. 
There are a vast number of detection schemes that have been developed to address these 
challenges including enzyme linked immunosorbent assay (ELISA), western blot, reverse phase 
protein array, and a multitude of biosensor assays. Of these, ELISA has emerged as the major 
workhorse for protein detection, especially in the clinical setting. This method relies on immuno-
capture and subsequent detection using tracer antibodies and enzyme-substrate interactions to 
produce a detectable signal, typically a fluorescent or colored species. Despite extremely low 
limits of detection and high specificity incurred due to the dual antibody recognition, ELISA still 
suffers from long analysis times, limited dynamic ranges, and difficulty in multiplexing. 
Additionally, though protocols are well-established and automation available, the quality of 
results can still depend on the experience of the analyst. Alternatively, numerous biosensors have 
been developed for protein detection as well. In general, they rely on a capture agent, typically 
an antibody, immobilized on a transducer which, among others, may be electrochemical, 
physical, or photonic in nature. 
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One such biosensing platform is the silicon photonic microring resonator platform developed 
by the Bailey group. The past several years have seen the development of this platform from 
proof of principal studies as a tool for biomolecular detection to a more recent focus on 
applications of biologically relevant targets. 
 
1.2 INSTRUMENTATION 
For some time, a major focus of the Bailey group has been the development and application 
of the silicon photonic microring resonator system. This instrumentation leverages refractive-
index based measurement to create a biosensing platform that is highly sensitive, versatile, and 
highly multiplexed. The details of the instrumentation have been explained in great detail by 
Iqbal et al. 2010
5
. In this section, in order to facilitate the discussion of my contributions to assay 
development, I present a general overview of the instrumentation. Recent improvements to the 
instrumentation which allow for greater multiplexing and integrated fluidics are discussed in 
section 1.6. 
The basis for these sensors are optical microring resonators fabricated in silicon-on-insulator 
material. Light is coupled into linear waveguides through free-space via grating couplers where it 
undergoes total internal reflection while traveling down the waveguide. It eventually exits the 
chip via another set of grating couplers to be detected by a photodetector. Adjacent to each linear 
waveguide is a microring resonator 30 μm in diameter. An external cavity tunable laser is used to 
sweep a 12 nm spectral window, and by monitoring the wavelengths that pass through the sensor 
chip an attenuation in transmission is observed at the resonance wavelengths. The evanescent 
field resulting from total internal reflection inside the linear waveguide couples light into the 
microring when it meets the resonance condition 
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mλ=2πrneff 
where m is an integer, λ is the wavelength of light, r is the microring radius, and neff is the 
effective refractive index. As is evident from the above equation, as the effective refractive index 
at the surface of the microring changes, the location of the resonance wavelength changes. This 
change is monitored in real time as total shift in pm. 
Sensors are fabricated in silicon-on-insulator material using standard semiconductor 
fabrication processes. Following formation of the microrings, waveguides, and grating couplers 
as well as other on-chip features used for optical alignment, the chips are coated with a 
commercial perfluoropolymer cladding layer. Annular openings are created over the sensor rings 
using photolithography and reactive ion etching to allow for solution to come into contact with 
the sensor rings, with several sensors remaining covered to serve as on-chip thermal controls. A 
sensor chip and individual microring are pictured in figure 1.1 along with an illustration of the 
shift in resonance wavelength and an example of the real-time monitoring of analyte binding. 
The microring resonator instrumentation has been used for the detection of proteins, nucleic 
acids, whole viruses, and toxins
6-10
. Detection has been demonstrated in buffer systems as well as 
complex matrices in both single- and multiplex fashions
11-14
. Additionally, this platform has been 
used for antibody screening and reaction condition profiling
15,16
. 
 
1.3 SENSOR FUNCTIONALIZATION 
In order to use the sensor chips for detection, the microrings must first be functionalized with 
specific capture probes for the analyte of interest as well as an on-chip control to account for 
non-specific binding. Capture probes used in the work described herein consist of either 
monoclonal antibodies, single-stranded DNA, or, in the case of some controls, polyclonal 
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antibodies. The specific surface chemistry and manual techniques employed vary between 
studies and are discussed in detail in their respective sections; however, the general outline is as 
follows. 
Sensor chips are cleaned with a piranha solution to remove any possible organic 
contaminants on the surface of the microrings, exposing the native oxide layer for further 
chemical modification. Silane chemistry is then used to install a functional moiety [S-HyNic (6-
hydrazinonicotinamide)] on the surface of the rings. In a separate step, the capture probe is 
modified to contain the 4-FB (4-formylbenzamide) moiety. Following HyNic modification of the 
chip, the modified capture probe is either flowed over or spotted onto the surface. The HyNic 
and 4-FB moieties form a stable hydrazine bond which covalently links the capture probe to the 
surface of the sensor ring. Typically, the chip surface is then blocked using either a high 
concentration of BSA or a commercial blocking reagent. 
In more recent applications, a shift has been made away from the HyNic/4-FB scheme to one 
using BS3 (Bis[sulfosuccinimidyl] suberate). In this scheme the chip is exposed to APTES ((3-
aminopropyl)triethoxysilane) followed by the BS3 linker. The capture agent is then spotted onto 
the chip either by hand or with an automated spotter, neither necessitating chemical modification 
of the capture agent. After an incubation time to allow for formation of the covalent bond 
between the BS3 and the capture agent, the chip surface is either coated with a reagent to prevent 
denaturation of the antibodies and stored dry or rinsed with a commercial blocking agent and 
stored wet until use. Thus far, this method appears to be equally effective in creating available 
binding sites on the sensors and is both more amenable to automated spotting procedures and 
significantly faster at high plexity. 
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1.4 DETECTION METHODOLOGY AND FLUIDICS 
Following functionalization, the sensors are loaded into a fluidic cartridge for use. The 
cartridges consist of an aluminum chip holder, Mylar fluidic gasket, and Teflon containing fluid 
inlet and outlet ports. With the exception of the newest instruments, which are discussed in 
section 1.6, external syringe pumps are used to drive flow through the channels over the chip 
with typical flow rates between 10 and 30 μL/min. Several fluidic geometries are available which 
allow for either 1, 2, or 4 fluidic channels. In this way, multiple experiments may be run 
simultaneously on the same sensor chip. 
The typical experimental protocol involves establishing a baseline in the running buffer 
followed by flowing the sample of interest, either a mixture in buffer or a complex matrix, for 
initial binding of the analyte. This is followed by a return to running buffer and any subsequent 
signal enhancement scheme employed (these are described in section 1.5). 
Quantitation consists of measuring the total shift after analyte binding or measuring the 
initial slope of the binding curve. The former is beneficial in situations where the initial slope is 
difficult to accurately observe, such as when subtraction of large off-target signal is required, or 
when employing secondary or tertiary binding for signal enhancement. The main drawback to 
this method is the long analysis times sometimes required to achieve binding equilibrium at the 
sensor surface. Using initial slope of the binding curve for quantitation removes this drawback 
and allows for discrimination between high concentrations which, if allowed to come to 
equilibrium, would saturate the binding sites on the sensors. However, it is typically only applied 
to primary binding and is difficult to employ with accuracy in complex matrices. 
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1.5 SIGNAL ENHANCEMENT METHODS 
Though biomolecule detection on the microring resonator system in a label-free format as 
described shows sufficient limits of detection for many applications, it is often helpful to employ 
a subsequent binding interaction which can both further decrease limits of detection and increase 
specificity
6,11
. Despite losing the appeal of a “label-free” format, there are significant benefits to 
using these secondary recognition steps. 
Adding a second specific binding interaction in a sandwich format, for example adding a 
tracer antibody which recognizes a separate epitope from the capture antibody, adds a second 
layer of specificity to the detection scheme. This confirms that the observed signal is arising 
from the analyte of interest and not from non-specific binding, a major issue in complex 
matrices. Additionally, in complex matrices the primary signal is often indistinguishable from 
background even after correction with off-target sensors. Therefore, a secondary interaction is 
often the only way to observe an analyte-specific signal. Several of our group’s publications 
show the use of tracer, sometimes called “secondary,” antibodies for added sensitivity and 
specificity on the microring resonator platform
10,12
. In most instances, the sensor chips are 
functionalized with a capture antibody, sample containing the analyte is flowed over the surface 
of the chip, followed by secondary antibody solution, showing a separate shift for both primary 
and secondary binding. A similar method can be used for the detection of nucleic acids wherein 
the capture and secondary probes are complementary to different ends of the single-stranded 
target. 
Once we have taken a step away from the benefits of “label-free” detection, it becomes 
obvious to ask the question of how best to leverage the subsequent binding to generate the most 
signal possible. As the ring resonator system is highly sensitive to the size of the species binding 
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to the sensor, an attractive technique is to use a method in which the label is extremely massive 
compared to the analyte of interest. This is accomplished by following primary binding of the 
analyte by the binding of a biotinylated tracer antibody. This is then followed by the binding of a 
streptavidin-coated magnetic bead with diameters in the low 100s of nm. Chapters 3 and 4, 
adapted from Luchansky et al. 2011 and McClellan et al. 2014, detail the development of signal 
enhancement techniques using magnetic beads both with and without a magnetic field for 
directed bead binding
13,17
. 
Alongside the development of bead-based signal enhancement methods, an enzyme-based 
signal enhancement technique was developed. In this method, primary binding is followed by the 
binding of a biotinylated tracer antibody. The subsequent binding of streptavidin conjugated 
horseradish peroxidase catalyzes the formation of a precipitate on the surface of the rings. This 
precipitate creates a massive resonance shift on the order of nm, allowing for the detection of 
even a single bound analyte. The development of the method is described in detail by Kindt et al. 
2013
18
. 
Following the development of these two methods of signal enhancement, I conducted a side-
by-side comparison between the two in order to determine which method provided the greatest 
enhancement in signal, lowest limits of detection, and which would be most suitable for 
automation using the built-in fluidic systems of the newest instrumentation. The results from 
these studies are presented in chapter 5. 
 
1.6 TRANSITION TO MAVERICK INSTRUMENTS 
The majority of the work discussed in the following chapters was performed on the early 
models of the microring resonator instruments; however, the final project discussed was 
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performed on the new instrumentation. Though described earlier, it is worth restating that these 
instruments scan a spectral window of 12 nm, tracking a single dip in transmission in time. They 
include a single laser integrated into each instrument. The sensor chips employed by these 
instruments contain 32 microrings of which 24 are available for functionalization and sensing 
and 8 serve as on-chip thermal controls. 
More recently, a newer generation of instruments has been developed, called the Maverick 
system. This system has several advantages over the initial instrumentation. Firstly, scanning 
width of the spectral window is increased several times, allowing for the simultaneous tracking 
and fitting of several transmission dips. This increases the precision with which relative shifts are 
tracked, reducing the frequency with which data must be discarded due to mis-tracking. 
Additionally, a single laser is used (housed in the “master” module) and split between a total of 4 
instruments, greatly reducing the cost of subsequent “slave” modules. Furthermore, the Maverick 
instrumentation employs sensor chips which contain 132 sensor rings of which 4 serve as 
thermal controls and 128 are available for sensing. These 128 rings are organized into 32 groups 
of 4 which are connected by channels in the perfluoropolymer cladding layer. A single group is 
thus necessarily functionalized with the same capture probe and provides a 4 times redundant 
measurement. Chips can be functionalized with fluidic gaskets up to 4-plex, by hand spotting 
methods up to 8-plex, and by automated spotting methods up to 32-plex. This allows for a much 
higher multiplexing capability compared to the early instrumentation, a necessity if we are to 
begin to tackle complex biological problems. 
The single innovation in the Maverick systems which has had perhaps the largest impact on 
the operation of the instrumentation is the integration of automated fluidics. The fluidic system is 
designed to draw sample from a standard 96-well plate in a single- or 2-channel format. From a 
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practical standpoint, this automation allows for data acquisition without constant monitoring by 
the user. This allows for multiple experiments to be run concurrently across multiple instruments 
and/or for wet lab work or data analysis to be conducted at the same time as experiments are run, 
something that was very difficult on the earlier instruments. From a data improvement 
standpoint, this automation allows for much more precise and reproducible fluid delivery, 
eliminating much of the error due to human reagent handling. Additionally, reduced lengths and 
inner diameter of the inlet tubing decrease the time it takes samples to reach the sensor surface, 
reducing any possible broadening of fluid interfaces through diffusion in the tubing. A high level 
of automation allows for the development of assays that are more representative of real-world, 
clinical applications and will be a crucial aspect of the transition between the research laboratory 
and the clinical laboratory. 
Excitingly, though not employed the in studies discussed in this document, the next 
generation of instruments, called the M24, has ability for the user to load 12 sensor chips at a 
single time. Each chip contains 132 rings in a 2-channel format (i.e. 24 separate experiments). 
These chips can then be run in sequence using the integrated automatic fluidics. The automation, 
throughput, and multiplexing possibilities of this next generation of instrumentation is ideally 
suited to large-scale biological studies with assays initially developed on the Maverick systems. 
This opens up a whole world of studies to our group that would otherwise be extremely labor- 
and time-intensive. 
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1.8 FIGURES 
 
Figure 1.1. (a)Photograph of sensor chip containing 64 sensor rings, 32 of which are used in 
any experiment, and scanning electron micrograph of a single microring resonator showing 
adjacent linear waveguide and annular opening in the perfluoropolymer cladding layer. (b) 
Illustration of shift in transmittance dip (from the black trace to the blue trace) upon binding of 
biomolecule to the sensor surface. (c) Example of real-time monitoring of a binding event. In this 
case, Bean pod mottle virus (BPMV) is captured on an anti-BPMV functionalized microring. 
The arrow indicates sample introduction; * indicates a return to running buffer. 
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Chapter 2 
 
Label-Free virus detection using silicon photonic microring 
resonators 
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This chapter is adapted from “Label-free virus detection using silicon photonic microring 
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Elsevier © 2012. 
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2.1 ABSTRACT 
Viruses represent a continual threat to humans through a number of mechanisms, which 
include disease, bioterrorism, and destruction of both plant and animal food resources. Many 
contemporary techniques used for the detection of viruses and viral infections suffer from 
limitations such as the need for extensive sample preparation or the lengthy window between 
infection and measurable immune response, for serological methods. In order to develop a 
method that is fast, cost-effective, and features reduced sample preparation compared to many 
other virus detection methods, we report the application of silicon photonic microring resonators 
for the direct, label-free detection of intact viruses in both purified samples as well as in a 
complex, real-world analytical matrix. As a model system, we demonstrate the quantitative 
detection of Bean pod mottle virus, a pathogen of great agricultural importance, with a limit of 
detection of 10 ng/mL. By simply grinding a small amount of leaf sample in buffer with a mortar 
and pestle, infected leaves can be identified over a healthy control with a total analysis time of 
less than 45 minutes. Given the inherent scalability and multiplexing capability of the 
semiconductor-based technology, we feel that silicon photonic microring resonators are well-
positioned as a promising analytical tool for a number of viral detection applications. 
 
2.2. INTRODUCTION 
Whether through direct or indirect means, viruses represent a menacing and omnipresent 
threat to humanity. Worldwide, many millions of people each year die or suffer from infections 
of viruses such as influenza, rotavirus, HIV, and measles, amongst many others, and viruses also 
pose a threat in the form of bioterrorism. Another key, though often overlooked, threat posed by 
viruses is to global food production, where viruses can cause significant decreases in crop quality 
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and yield. The battle to prevent or avert disaster in each of these affected sectors is 
fundamentally tied to the ability to detect the presence of these nanoscopic species. 
Current viral detection methods can be broken down into three categories based upon the 
type of signature analyzed
1. Serological methods take advantage of the host organism’s natural 
immune response to measure antibodies generated in response to infection. While commonly 
employed, these approaches are often limited by the time required for the infection to generate a 
measurable immune response, often requiring weeks to months to achieve 
1,2
. Another common 
approach to virus detection relies upon the detection of viral proteins, DNA, or RNA. In 
particular, nucleic acid analysis, via polymerase chain reaction (PCR) or reverse transcriptase 
(RT)-PCR, respectively, offers very high sensitivity due to the amplification inherent in PCR. 
There exist a number of methodologies that have been applied to the detection of whole, intact 
viruses—an approach that has potential advantages of reduced sample preparation and more 
rapid analysis. Not surprisingly, in pursuit of rapid and sensitive analysis there has recently been 
considerable activity in the development of micro- and nanoscale tools for viral targets for many 
different applications.  
In this manuscript, we report the application of silicon photonic microring resonators for the 
label-free detection of viruses. Microring resonators are chip-integrated microcavities supporting 
optical modes that are exquisitely sensitive to the local dielectric environment. When 
functionalized to present analyte-specific capture agents, these devices are transformed into 
sensitive biomolecular sensors, as the wavelengths meeting the cavity resonance condition shift 
upon target binding-induced changes in the local refractive index, as shown in Figure 2.1. We 
have previously demonstrated the utility of arrays of microring resonators for the label-free 
detection of protein and nucleic acid targets in both single- and multiplexed formats 
3-5
. Herein 
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we use the same platform for quantitating whole virus particles. Notably, Vollmer et al. 
previously utilized a related type of sensor, based upon a microsphere optical resonator, to detect 
single influenza particles in a buffer solution 
6
. 
In this manuscript, we describe the quantitative detection of viruses from both buffer 
solutions and leaf extract using arrays of chip-integrated microring resonators. These devices are 
batch fabricated using well-established semiconductor processing methods making them 
intrinsically multiplexable and inexpensive to mass produce. Therefore we feel that this 
technology could be promising for point-of-care detection of viruses from within complex 
matrices and for a range of bioanalytical applications. As a model virus for technology 
validation, we have chosen a target with strong agricultural importance: Bean pod mottle virus 
(BPMV). BPMV is an icosahedral RNA virus with a mean diameter of 28 nm and a mass of ~7 
MDa 
7-9
. It is the most common viral soybean (Glycine max) pathogen throughout much of the 
south, southeast, and Midwest portions of the United States and Canada, and it is responsible for 
decreased quality and yield of soybean production 
9
.  Severe infections can lead to up to 52% 
losses in crop yield due to smaller seed size and discoloration
10
. Additionally, co-infection of 
crops with BPMV and Soybean mosaic virus (SMV) can lead to devastating reductions of crop 
yields of up to 85% 
11,12
. Because of the large number of samples to be analyzed in monitoring 
the speed and breadth of disease transmission, it is clear that techniques capable of detecting 
viruses with minimal sample preparation and rapid time-to-result are valuable. Herein, we utilize 
scalable, silicon photonic detection technology to quantitatively detect viruses in BPMV infected 
soybean leaf extracts in a simple, rapid, and label-free assay format. 
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2.3. MATERIALS AND METHODS 
2.3.1 Materials. Unless otherwise specified, reagents were obtained from Sigma-Aldrich (St. 
Louis, MO) and used as received. Monoclonal antibodies to BPMV (CAB 46400), SMV (CAB 
33300), Alfalfa mosaic virus (AMV; CAB 87601), Tobacco ringspot virus (TRSV; CAB 64000), 
and a BPMV ELISA kit were purchased from Agdia (Elkhart, IN). The 3-N-((6-(N’-
isopropylidenehydrazino))nicotinamide)propyltriethoxysilane (HyNic silane) and succinimidyl 
4-formyl benzoate (S-4FB) were purchased from Solulink (San Diego, CA). Dulbecco’s 
phosphate buffered saline (PBS), was reconstituted in deionized water and the pH adjusted to 
either 7.4 or 6.0 with 1M HCl or 1M NaOH. BSA-PBS buffer consisted of 0.1 mg/mL bovine 
serum albumin (BSA) in pH 7.4 PBS. The surface blocking buffer consisted of 2% BSA in pH 
7.4 PBS. Zeba spin filter columns were purchased from Pierce (Rockford, IL).  
Purified BPMV was isolated from infected leaf samples soybean cultivar Williams 82 
infected with BPMV isolate WP2 as described Ghabrial et al. (1977) 
13
. Leaves were collected 
from age-matched healthy and BPMV-infected Williams 82 soybean at 2 weeks after 
inoculation. 
2.3.2 Instrumentation and microring sensor array substrates. The instrumentation 
utilized to measure shifts in microring resonance wavelengths and sensor substrates were 
designed in collaboration with and acquired from Genalyte, Inc. (San Diego, CA), and were 
described previously 
3,14
. Briefly, sensor chips, each having an array of 32 individually 
addressable microring resonators accessed by a linear waveguides with terminal diffractive 
grating couplers, were fabricated on silicon-on-insulator wafers. The entire surface of the 
substrate was uniformly coated with a perfluoropolymer and annular openings were created over 
24 of the microrings via reactive ion etching, allowing solution to come into contact with the 
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those sensor elements. The remaining 8 microrings remain occluded and are used as thermal 
controls, as they are not affected by chemical or biomolecular binding events. 
Sensor substrates were loaded into a previously described microfluidic cartridge and light 
from a tunable external cavity laser (center wavelength 1560 nm) coupled into the input grating 
coupler accessing a single microring. The laser wavelength was then swept through a 12 nm 
spectral window and resonances determined as negative attenuations in light intensity outcoupled 
through the output grating coupler. This process was repeated for the entire array of 32 
resonators, enabling near real-time measurement of shifts in resonance wavelength. Solutions 
were flowed across the sensor array as directed by the microfluidic gasket under the control of a 
syringe pump. 
2.3.3. Functionalization of sensor array surface. The sensor chip was cleaned with a 
piranha solution (3:1 H2SO4:30% H2O2), followed by copious rinsing with water, and then rinsed 
with isopropanol and dried in a stream of nitrogen
a
. To introduce analyte-specific capture agents, 
the sensor chip was immersed for 20 minutes in a 1.25 mg/mL solution of HyNic Silane in 95% 
ethanol and 5% DMF, which installs a HyNic linker on the surface of the microrings. Separately, 
antibodies were conjugated to S-4FB molecules through the following procedure. Antibody 
solutions were buffer exchanged using Zeba spin filter columns into PBS pH 7.4 and reacted 
with a 10-fold molar excess of S-4FB (0.1 mg/mL in DMF) at room temperature for 2 hours. 
Unreacted S-4FB was removed via spin filtration and the buffer exchanged to PBS pH 6.0. The 
concentration of antibody in solution was determined by absorbance at 280 nm, as measured on a 
NanoDrop 1000 spectrophotometer (Thermo Scientific). Immediately before surface 
conjugation, aniline
15
 (to a final concentration of 105 mM) was added to a solution of 
                                                             
a Caution: piranha solution must be handled with care as it reacts violently with organic compounds. 
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approximately 40 µg/mL of the 4FB-modified antibody and this solution was flowed across the 
microrings at 2 µL/min for 70 min. The sensor chip was then rinsed with a pH 2.2 glycine buffer 
to remove non-covalently attached antibody and stored in BSA-PBS at 4°C until use. Sensor 
chips were typically functionalized with multiple antibodies, having specificity for BPMV and 
other soybean viruses, with rings not recognizing BPMV able to be used to correct for non-
specific adsorption in complex samples.  
2.3.4. Sample preparation and assay procedure. Standard concentrations of BPMV were 
prepared by serial dilution of the stock concentrated virus in BSA-PBS. Two leaf extract samples 
were prepared by grinding approximately 100mg of leaf material in a mortar and pestle with 1 
mL of BSA-PBS buffer until homogeneous. Solid plant debris was quickly removed via a 5 
minute centrifugation at 10,000 rcf. The supernatant was diluted 200-fold with BSA-PBS before 
analysis. 
Prior to sample analysis, the sensor chip was blocked with blocking buffer and a baseline 
established in BSA-PBS buffer. The sample was flowed over the surface for 30 minutes at 10 
µL/min followed by a 5 to 10 minute buffer rinse. A pH 2.2 glycine buffer rinse was then used to 
regenerate the chip surface. The process was repeated for subsequent samples. 
2.3.5. Data analysis. The total shift in resonance wavelength after 30 minutes of virus 
binding to antibody-modified microrings was measured and used to generate a calibration curve 
for BPMV concentration. Despite blocking, leaf extract solutions gave some non-specific 
binding and therefore the response from the isotype control microrings was subtracted from that 
of the anti-BPMV functionalized rings (Figure 2.2). 
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2.4. RESULTS AND DISCUSSION 
2.4.1 Sensor Specificity. As a test to determine if BPMV could be selectively detected, a 
four channel microfluidic gasket was used to immobilize four different antibodies on a single 
sensor array, each specific for one of four different soybean viruses, BPMV, SMV, TRSV, and 
AMV. A purified sample of BPMV was then flowed over the entire sensor array. As shown in 
Figure 2.3, large shifts in resonance wavelength are only recorded for the microrings presenting 
anti-BPMV, confirming the analyte-specific detection of BPMV.  
2.4.2. Sensor Calibration. We then sought to understand the concentration sensitivity of the 
platform for quantitative BPMV analysis, which is a function both of the fundamental device 
sensitivity as well as the affinity of the biomolecular recognition even (the affinity of the 
antigen-antibody interaction, in this case). Using a two channel microfluidic architecture, 12 
microrings were selectively functionalized with the anti-BPMV antibody and another 12 
microrings with the anti-SMV antibody, which served as a negative control to correct for non-
specific binding. Standard solutions containing BPMV at concentrations ranging from 25 ng/mL 
to 1000 ng/mL in BSA-PBS were successively flowed across the entire sensor array, with sensor 
regeneration in between each concentration, and the relative shifts in resonance wavelength for 
each microring were monitored in near real-time. Figure 2.4a shows an overlay of the responses 
for the anti-BPMV modified microrings. Negligible binding was observed on the anti-SMV 
rings, consistent with the previously determined sensor specificity. Plotting the relative shifts in 
resonance wavelength upon switching back to pure buffer after 30 minutes of binding versus 
concentration BPMV allow for the construction of a sensor calibration curve, as shown in Figure 
2.4b. The error bars on each point correspond to 95% confidence interval from n≥12 
measurements. The calibration curve is fit with a second-order polynomial (R
2
=0.987) since, as 
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expected, the binding response begins to saturate at higher BPMV concentrations. The limit of 
detection was empirically determined by finding the lowest concentration that generates a 
measurable response to be 10 ng/mL, which corresponds to ~1.4 pM.  
2.4.3. Demonstration in Leaf Samples. A key advantage of our silicon-based analysis 
platform is that sensors can be mass produced at very low cost, and label-free operation removes 
requirements for multiple detection reagents and/or extensive sample preparation, such as 
fluorescent or enzymatic labeling. These qualities position microring resonators as a potentially 
useful technology for “in-the-field” agricultural diagnostics. Importantly, the rapid and 
widespread analysis of easily attainable samples might allow timely intervention to, for example, 
limit the regional propagation of viral infections. Therefore, we sought to challenge our platform 
with a more real-world applicable analytical challenge, focusing on the relatively rapid (< 1 
hour) analysis of healthy and BPMV-infected soybean leaves. 
Portions of leaves harvested from both healthy and BPMV-infected soybean plants were 
simply ground with a small amount of buffer for one minute in a mortar and pestle.  Solid plant 
debris was removed via centrifugation, diluted, and flowed directly across a sensor array that had 
microrings functionalized with anti-BPMV and anti-SMV. Figure 2.5 shows that the presence of 
BPMV was clearly evident in the infected leaf sample, as the resonance wavelength shift was 
significantly larger than that from the healthy leaf sample. Notably, the analysis of whole leaf 
samples (both healthy and infected) was complicated by non-specific adsorption of unknown 
interferences (see figure 2.2); however, the presence of anti-SMV control rings allowed this non-
specific response to be simply subtracted from the signals from the anti-BPMV-modified sensor 
elements. This corrected response was considered against the previously established standard 
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curve, and the concentration of BPMV in the extract was determined to be 78.7 μg/mL, which 
corresponded to 0.79 mg BPMV/ g leaf. 
The most commonly used method for detection of BPMV is the sandwich enzyme linked 
immunosorbent assay (ELISA) 
11
. This method, though highly sensitive, has a number of 
drawbacks that make it less than ideal for certain applications. For example, per the 
manufacturer’s instructions, the BPMV ELISA assay is only to be used for detecting the 
presence or absence of infection, providing no quantitative information about viral load. 
Moreover, standard ELISAs typically take multiple hours to perform and are only capable of 
detecting a single target antigen from within a sample volume. By comparison, this report 
describes the quantitative analysis of viral load within a 45 minute total assay time, without the 
need for extensive sample handling or pre-treatment. To our knowledge, this represents the most 
rapid determination of BPMV infections in terms of both sample preparation and analysis. 
Furthermore, while it is beyond the scope of this report, the microring resonator analysis 
platform is intrinsically multiplexable on account of its origins in semiconductor fabrication, and 
we have previously shown that multiple biomolecular signatures can be simultaneously 
quantified from a single sample with no loss in device performance 
4,5,16
. The prospects of 
detecting multiple viruses from within a single leaf sample is very attractive for crop diagnostics 
as co-infection with multiple viruses is known to dramatically increase losses in crop yields
12,17-
21
. Therefore, we feel that the silicon photonic microring resonator platform has the potential to 
be a powerful analytical tool for agricultural detection applications 
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2.5. CONCLUSIONS 
We have demonstrated the ability to quantitatively detect bean pod mottle virus (BPMV) 
both in buffer and in complex leaf extracts using silicon photonic microring resonator 
technology. The simple extraction method and direct detection of intact viruses, combined with 
comparatively short analysis times of <1 hour, provide a straight forward assay that offers 
advantages over many commonly employed methods. Additionally, the ability to fabricate highly 
multiplexed sensors will allow for identification of co-infections with no additional sample 
preparation or analysis, providing a powerful tool for viral detection that can span applications 
from healthcare and bioterrorism surveillance to agricultural monitoring. 
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2.7 FIGURES 
 
 
Figure 2.1. Illustration of viral detection using silicon photonic microring resonators. Microring 
functionalized to present antibodies (purple) specific for the virus of interest (blue icosahedron) 
(a) support optical resonances at particular wavelengths that are extremely sensitive to antigen 
binding induced changes in the local refractive index. As viruses in a sample bind to the 
antibodes on the microring, the resonance shifts to longer wavelengths (b), and this shift is 
monitored in real time (c) to allow quantification of the target virus. In (c) the arrow indicates the 
time at which the sample is introduced and the * indicates the return to running buffer. 
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Figure 2.2. Graphs showing the response of BPMV and control sensors to the extract from a 
BPMV infected leaf (a) and a healthy leaf (b). The black trace is the response from anti-BPMV 
functionalized sensors, the red trace, after correction for nonspecific binding to control sensors, 
the blue trace.  Samples are introduced at 2 minutes, and the * represents a change back to pure 
buffer. 
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Figure 2.3. Sensor response to a purified sample of BPMV by sensors functionalized with 
antibodies to AMV, BPMV, SMV, and TRSV. The specificity of the sensors is clearly evident as 
the only sensors that respond to the BPMV virus are those that present anti-BPMV antibodies. 
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Figure 2.4. (a) Graph showing the overlaid sensor responses for a representative ring to 
increasing concentrations of BPMV, arrow indicates the addition of BPMV standards, a dashed 
line is located at 0 shift; (b) graph showing the calibration curve for BPMV with a second-order 
polynomial fitting. The blue “X” indicates the response from the 1:200 dilution of the extract 
from a BPMV infected sample. Error bars represent the 95% confidence interval from n ≥ 12 
measurements. 
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Figure 2.5. Sensor response to diluted extracts from soybean leaves. The red trace represents a 
1:200 dilution of the leaf extract from a BPMV infected sample. The blue trace represents a 
1:200 dilution of the leaf extract from a healthy sample. 
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Chapter 3 
 
Sensitive on-chip detection of a protein biomarker in human serum 
and plasma over an extended dynamic range using silicon photonic 
microring resonators and sub-micron beads 
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3.1 ABSTRACT 
We demonstrate a three-step assay on a silicon photonic microring resonator-based 
detection platform that enables the quantitation of the cardiac biomarker C-reactive protein 
(CRP) over a dynamic range spanning six orders of magnitude. Using antibody-modified 
microrings, we sequentially monitor primary CRP binding, secondary recognition of bound 
CRP by a biotinylated antibody, and tertiary signal amplification using streptavidin-
functionalized beads. This detection methodology is applied to CRP quantitation in human 
serum and plasma samples. 
 
3.2 INTRODUCTION 
Most new biosensor development efforts focus almost exclusively on improving detection 
sensitivity for a particular target analyte. While this is clearly a vital metric, assay dynamic 
range is also an important attribute that critically influences clinical utility. The dynamic 
range challenge is even more pronounced for multiplexed analyses, where both intra- and 
inter-analyte concentrations can vary widely. For example, the cardiovascular risk biomarker 
C-reactive protein (CRP) can increase by a factor of 10,000 in serum during an acute phase 
response.
1
 Moreover, protein concentrations in human plasma are known to vary over 11 
orders of magnitude.
2
 Whereas single-analyte assays can incorporate repeated dilutions, 
multiplexed analyses of antigens that natively vary in magnitude represent a significant 
analytical challenge. 
Recently, chip-integrated, silicon photonic microcavities have been developed for a 
number of biosensing applications.
3
 Importantly, the scalability and multiplexing capability 
inherent to these semiconductor-based devices make them attractive for many high volume 
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applications, including in vitro clinical diagnostics. Because they are responsive to binding-
induced changes to the refractive index (RI) environment near the resonator surface, these 
sensors are intrinsically label-free. Our group has previously investigated the applicability of 
microring optical resonator arrays for protein analysis and demonstrated the detection of 
analytes in both single
4
 and multiplexed
5
 formats using an initial slope-based quantitation 
technique. This approach features a superior linear dynamic range of ~3 orders of magnitude, 
while maintaining a limit of detection (LOD) comparable to that of a commercial enzyme-
linked immunosorbent assay (ELISA). We also have shown that the incorporation of a 
secondary antibody recognition event can further lower the limit of detection while also 
increasing assay specificity in complex sample matrices.
6
 However, because of surface-
saturation effects, quantitation at higher concentrations is restricted, resulting in a more 
limited dynamic range similar to that of other sandwich immunoassays.
7
 
In this paper, we report the analytical utility of a three-step assay format in which 
primary, secondary, and bead-enhanced tertiary binding events are observed in series in order 
to sensitively quantitate the presence of an antigen over a broad (~10
6
) dynamic range. As 
shown in figure. 3.1, the primary and secondary measurements are conducted as described 
previously.
4,6
 The subsequent tertiary detection event involves the binding of streptavidin 
(SA)-coated, sub-micron (~100 nm diameter) beads to biotinylated secondary antibodies. 
Similar to previous reports using nanoparticles,
8-10
 carbon nanotubes,
11
 and enzymatic 
amplification
12
 to enhance the signal of RI-based sensing devices, our tertiary binding assay 
lowers the LOD by enhancing the optical signal arising from a single bound antigen. 
However, more important here is the integration of a consecutively run assay that includes 
the real-time observation of all three discrete binding regimes. This methodology broadens 
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the dynamic range to over six orders of magnitude.  
 
3.3 MATERIALS AND METHODS 
3.3.1. Materials. 3-N-((6-(N’-Isopropylidene-hydrazino))nicotinamide)propyltriethoxy-
silane (HyNic silane), succinimidyl 6-hydrazinonicotinate acetone hydrazone (S-HyNic), and 
succinimidyl 4-formyl benzoate (S-4FB) were purchased from Solulink (San Diego, CA).  
Capture and secondary antibodies to CRP (clones M701289 and clones M701288, 
respectively) were purchased from Fitzgerald Industries (Concord, MA).  Capture (MAB206, 
clone 6708) and biotinylated secondary (BAF206) antibodies for interleukin-6 were 
purchased from R&D Systems, Inc (Minneapolis, MN). Recombinant human interleukin-6 
and a human CRP ELISA kit (88-7502-28) were purchased from eBioscience (San Diego, 
CA). NHS-PEG4-Biotin was purchased from Thermo Scientific and dissolved in DMF to 
make a 20 mM stock solution.  Streptavidin-coated polystyrene/iron oxide beads with a mean 
diameter of 114 nm were purchased from Ademtech (Pessac, France).  Human CRP (95% 
pure from human blood) was purchased from Meridian Life Science.  CRP-depleted 
processed serum and CRP High Plasma (with a reported CRP content of 69.1 µg/mL based 
on a Roche Modular immunoassay) were purchased from SunnyLab (Sittingbourne, UK).  
Pooled normal human serum and single-donor human serum samples #1 and #2 (catalog 
number IPLA-SER-S, lot numbers K9207 BF 19 and 55-25114 WM 19, respectively) were 
purchased from Innovative Research (Novi, MI).  Fresh single-donor human plasma was 
collected from a healthy donor under a plan approved by the University of Illinois 
Institutional Review Board. Zeba spin filter columns and StartingBlock (PBS) were 
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purchased from Pierce (Rockford, IL).  Vivaspin molecular weight cutoff filters (5000 and 
50000 kDa) were purchased from GE Healthcare (Waukesha, WI). 
The capture anti-CRP antibody was immobilized onto the microring sensors using a 
DNA-encoding approach.
13,14
 30-mer DNA strands for the DNA-encoded CRP capture 
antibody immobilization were synthesized with a C6 spacer and 5′ amination by Integrated 
DNA Technologies (Coralville, IA).  The surface 30-mer sequence was 5'-
AAAAAAAAAAGCCTCATTGAATCATGCCTA-3', and the complement sequence 
conjugated to anti-CRP capture antibodies was  
5'-AAAAAAAAAATAGGCATGATTCAATGAGGC-3'.  The 3′- biotinylated 30-mer 
for the simulated human papillomavirus (HPV) DNA target, simulated HPV DNA 46-mer 
target, and HPV surface capture strand were also synthesized by Integrated DNA 
Technologies.  The sequences were  
5'-CTCTGGATAATAGAGAATGTAAAAAAAAAA-3',  
5'-TACATTCTCTATTATCCACACCTGCATTTGCTGCATAAGCACTAGC-3', and  
5'-AAAAAAAAAGCTAGTGCTTATGCAGCAAAT-3', respectively. 
PBS buffer was prepared from Dulbecco’s phosphate buffered saline from Sigma Aldrich 
(St. Louis, MO).  PBST buffer consisted of PBS buffer and 0.05% Tween-20.  The pH of 
buffers was adjusted using 1M HCl or 1M NaOH.  All other chemicals were obtained from 
Sigma-Aldrich and used as purchased. 
3.3.2. Antibody and DNA Modification. An aldehyde moiety is added to the surface 
capture DNA strand and its complement by incubation with a 20-fold molar excess of 5 
mg/mL S-4FB for 2-3 h at room temperature in 33% DMF in PBS pH 7.4.  Excess S-4FB is 
removed by buffer exchange using a 5-kDa molecular weight cutoff filter.  Capture antibody-
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HyNic conjugates are prepared by incubating the antibody with a 10-fold excess of 1 mg/mL 
S-HyNic at room temperature for 2 h.  Excess S-HyNic is removed by buffer exchange using 
Zeba spin filter columns.  For biotinylation, 0.5 mg/mL secondary anti-CRP M701288 in 
PBS pH 7.4 is incubated with a 10-fold molar excess of 20 mM NHS-PEG4-biotin for 3 h at 
room temperature.  Excess NHS-PEG4-biotin is removed by buffer exchange using Zeba spin 
filter columns.  Capture antibody- DNA conjugates are prepared by incubating the capture 
antibody-HyNic conjugate and the 4FB-modified surface DNA strand at a 1:20 protein:DNA 
ratio overnight at 4°C.  The mixture is purified using a Superdex 200 10/300 GL column on 
an AKTA FPLC, both from GE Healthcare, and fractions containing the antibody-DNA 
conjugate are concentrated and exchanged into PBS buffer using a 50-kDa molecular weight 
cutoff filter. 
3.3.3. Bead exchange and surface modification. Beads are exchanged into PBST buffer 
immediately before use to remove free streptavidin via the following procedure. First, 30 μL 
of 5 mg/mL streptavidin-coated beads are diluted to 150 μg/mL with PBST buffer and 
centrifuged at 10,000 g for 4 min.  The bead pellet is held at the bottom of the tube using a 
magnet while the supernatant is removed, leaving about 30 μL of solution.  The beads are 
then resuspended in 1 mL of PBST buffer by pipetting the solution up and down ~50 times 
with the tube bottom remaining in contact with the magnet.  This procedure is repeated for a 
total of 4 exchanges.  Directly before use in the assay, the final bead solution is adjusted to a 
concentration of 50 µg/mL using the absorbance value at 286 nm as determined by 
calibration based on direct dilution of non-exchanged beads.  For DNA detection, beads are 
conjugated to a secondary complementary DNA strand.  Streptavidin-coated beads are 
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incubated with a large excess of biotinylated DNA for at least 2 h.  The excess DNA is 
removed by buffer exchange according to the previously described method. 
3.3.4. Chip functionalization. Chips are batch-functionalized ex-situ by a spotting 
method.  After a 20-min sonication in ethanol, chips are immersed for 20 s in hot Piranha 
solution (3:1 H2SO4: 30% H2O2) [Caution: Pirahna solution must be handled with care as it 
can react violently with organic compounds.], rinsed with water, and dried under a stream of 
nitrogen.  Each chip is then spotted with a 30-µL drop of 1 mg/mL HyNic silane in 95% 
ethanol and 5% DMF and incubated at room temperature in an enclosed chamber for 30 min.  
The chip is then rinsed with ethanol and dried.  A 0.5-μL drop of 4FB-modified capture DNA 
strand is then manually pulled across the surface with a 2.5-L pipette tip, avoiding those 
rings which are to be used as controls.  The chip is then blocked by submersion in 
StartingBlock at 4ºC for at least 8 h. 
3.3.5 Experimental procedure. The fluidic cell and microfluidic system have been 
described previously.
4
  In these experiments, a Mylar gasket is used to direct flow to two 
microfluidic channels, each addressing 12 of the 24 active rings, allowing two experiments to 
be carried out on one chip.  A consistent amount of capture antibody is loaded by flowing 10 
µg/mL DNA-encoded anti-CRP M701289 at 2 µL/min until the antibody signal reaches ~140 
pm. To begin the procedure for the analysis of samples, PBST buffer is flowed over the 
surface to establish a baseline.  A 30 µL/min-flow rate is maintained for all assay segments. 
The sample or standard is introduced and allowed to flow over the surface for 20 min, 
followed by a buffer rinse.  In serum and plasma samples, this rinse is longer (~20 min) than 
the typical 3 min rinse to allow for desorption of non-specifically bound proteins.  The 
biotinylated secondary antibody is then flowed over the surface for 15 min followed by 
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another short buffer rinse (3-5 min).  Finally, streptavidin-coated beads (exchanged 
immediately before use as described above) are flowed over the surface for 16 min followed 
by a final buffer rinse.  For DNA detection, there is not a third binding step as the secondary 
detection strand is directly conjugated to the bead. 
3.3.6 Instrumental Setup. The microring resonator instrumentation and chips were 
acquired from Genalyte (San Diego, CA), and have been described in detail in previous 
publications.
4,15
 Briefly, each chip is fabricated with 32 active microring sensors covered with 
a perfluoropolymer cladding layer. Eight rings on each chip remain occluded by the polymer 
layer and serve as thermal controls. Twenty-four active sensors rings have an annular opening 
etched over the ring to enable exposure to the solution in the microfluidic channel. Each ring 
resonance is monitored via frequency attenuation in an adjacent linear waveguide. Input and 
output diffractive grating couplers are located at each end of the waveguide to enable 
independent determination of the optical cavity spectrum for each microring using a tunable, 
external cavity diode laser (center frequency: 1560 nm).   
3.3.7 Data analysis. Calibration curves for primary binding are generated by determining 
the initial slope as a function of analyte concentration, as described previously.
4
 Secondary 
and tertiary binding calibration curves are generated by plotting the total net relative shift of 
the secondary and bead binding, respectively.  Standard additions were prepared based on an 
initial estimate of the unspiked concentration in a diluted sample based on comparison to 
calibration plots generated in buffer.  Small increments of a concentrated CRP solution are 
added to aliquots of diluted sample and then analyzed in the above described manner.  
Standard addition plots are generated based on primary, secondary, or tertiary response as a 
function of the concentration of spiked CRP added, and CRP concentrations are determined 
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based on extrapolation of the linear regression fit to the x-intercept. Regression lines for 
calibration in buffer and standard additions were calculated using linear fitting functions in 
Origin Pro 8.5 software. 
 
3.4 RESULTS AND DISCUSSION 
As a representative analyte that is known to vary over a wide dynamic range in clinical 
samples,
1
 CRP is quantitated via a three-step assay protocol in buffer, human serum, and 
human plasma. 24-sensor chips were functionalized with a capture antibody against CRP (see 
section 3.3.4) leaving four sensors on each chip unfunctionalized to serve as controls. For 
each experiment, two microfluidic channels per chip were used, each having ten active 
sensors and two controls. 
As shown in the red trace in figure 3.1, the addition of 10
-1
 µg/mL CRP (t = 5 min) 
resulted in a visible primary binding response. Subsequent addition of biotinylated anti-CRP 
(t = 28 min) gave a ~3-fold larger response. Finally, addition of 100-nm SA-functionalized 
beads (t = 46 min) provided an even larger signal enhancement. At this relatively high 
concentration, secondary and tertiary amplification gave large signals, but they were not 
required for CRP detection. However, at lower concentrations such as 10
-3
 µg/mL CRP (blue 
trace in figure 3.1), amplification was necessary. At or below this concentration, no primary 
binding was detected, and the secondary binding showed ~1 pm resonance wavelength shift. 
Notably, addition of the beads gave nearly a 100-fold signal enhancement at this low 
concentration. Negative control experiments, in which biotinylated antibody and SA-beads 
were flowed over an anti-CRP-functionalized chip without initial CRP incubation, yielded no 
appreciable signal (figure 3.2). 
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After determining the nature of the three-step signal enhancement process, CRP standards 
were measured across a 5-order-of-magnitude concentration range using the sequential 
primary-secondary-tertiary assay protocol. As shown in figure 3.3, the response curves from 
the primary, secondary, and tertiary binding assays overlap, allowing continuous CRP 
calibration over a broad dynamic range (10
-4
 µg/mL to 10 µg/mL). The initial slope of 
primary binding (black squares) is important because, at high concentrations, the surface is 
nearly saturated. Thus, it is impossible to distinguish between high concentrations except by 
the rate at which they approach saturation.
4
 Using initial slopes, it is possible to quantify 
concentrations from 10
-2
 to >10 µg/mL in buffer. The dynamic range is extended (10
-3
 to >10
-
1
 µg/mL) by measuring the relative shift in resonance wavelength following addition of 
secondary antibody (red circles) and further expanded down to <10
-4
 µg/mL though the use 
of SA-bead enhancement (blue triangles). Using the bead-based enhancement, the overall 
assay LOD is ~3 × 10
-5
 µg/mL (~200 fM). 
The dynamic range of each step of the three-part analysis method has a region of overlap 
with one of the other steps (figure 3.3), providing the opportunity for confirmation of the 
measurement. For example, 10
-3
 µg/mL CRP is quantifiable by secondary detection, but 
tertiary amplification significantly increases the measurement precision as seen by a 
comparison across 80 sensors in 8 channels on 4 chips (figure 3.4/table 3.1). 
Following assay calibration, the same three-step detection protocol was applied to the 
quantitation of CRP in human plasma and serum samples. Because the expected range of 
concentrations of CRP in human blood is from 10
-1
 µg/mL to 10
3
 µg/mL, each sample was 
subjected to the same 1:1000 dilution into buffer, bringing concentrations into the range that 
could most accurately be quantified. This uniform dilution, as opposed to repeated dilutions, 
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also helped reduce non-specific adsorption of blood proteins and lowered the required sample 
volumes to less than ten microliters, making the assay amenable to fingerprick sampling. 
For the purposes of quantitation we utilized a standard addition method as it is amenable 
to the complex and variable clinical sample matrices.
16
 In this method, the diluted serum or 
plasma was first analyzed via the three-step assay, and the response was compared to the 
calibration curve (figure 3.3) to roughly estimate the CRP concentration range. Three 
appropriate samples with increasing standard additions were then successively analyzed, and 
the precise CRP concentration was determined via extrapolation. The wide variation in native 
CRP levels required user input into the standard addition procedure, as opposed to simply 
adding uniform amounts of standard. However, the overall methodology is amenable to 
automation; for example, an analytical system pre-programmed with the calibration 
information could utilize integrated microfluidics to create the appropriate standard additions 
on demand. 
Figures 3.5 and 3.6 show the results of these serum/plasma analyses. The colours in the 
graph indicate the method used to quantify the CRP concentration. The black bar indicates 
that a commercially obtained pooled plasma sample with elevated CRP was quantified using 
the primary binding response and found to have a CRP concentration of 57.5 ± 3.3 µg/mL. 
This value obtained on the microring resonator platform agreed reasonably well with the 
supplier’s provided value of 69.1 µg/mL. This result was in closer agreement than the results 
of an ELISA run in parallel, which gave a CRP concentration of 105 ± 11 µg/mL (table 3.2). 
The red bars indicate secondary binding-based detection, which was used to quantitate the 
CRP values in the pooled-donor normal serum, single-donor serum #2, and single-donor 
plasma. The blue bars indicate quantitation using the tertiary bead binding, which was 
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necessary to detect CRP within single-donor serum #1 as well as a commercially-available 
CRP-depleted serum sample (in which CRP had been removed by the vendor). Each of the 
samples analysed, with the exception of the CRP-elevated pooled plasma, had CRP levels 
less than 1 µg/mL, placing those donors in the low-risk range for cardiovascular disease.
1
 
Interestingly, for the CRP-depleted sample, analysis of a 1:100 dilution revealed CRP levels 
at 3×10
-5
 µg/mL. While this concentration is far below what would typically be found in 
human serum, it is noteworthy that this is similar to the lowest levels of CRP present in 
saliva.
17
 This means that the three-step assay format on the silicon photonic-based platform is 
amenable to quantifying CRP in all clinically-relevant sample matrices. 
In the course of our studies, we observed that several of the serum and plasma samples 
gave abnormally large signals for primary binding to microrings functionalized with the 
capture anti-CRP antibody, but a much smaller secondary binding response. These 
interactions, which we attribute to cross-reactivity between the primary antibody and some 
unknown component, highlight the fact that sample-to-sample heterogeneity can greatly 
complicate analysis in clinical samples.  In the case of the pooled plasma with elevated CRP, 
the primary binding signal was much larger than any of the off-target responses, and thus it 
did not interfere with primary response-based quantitation. Though this is not a clinically 
relevant problem since significantly elevated CRP levels are clearly evident with both 
primary and secondary analysis, the use of a different capture antibody or improved non-
fouling surface could provide more accurate quantitation in this regime.   However, for the 
single-donor plasma and serum samples, as well as the pooled normal serum, the primary off-
target signal indicated abnormally high CRP content. Fortunately, the proportionally smaller 
secondary binding response increased the specificity of the assay, giving more reliable levels 
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of CRP. As alluded to earlier, the three-step measurement format described herein has the 
added benefit that an analyte is measured at multiple levels, increasing the specificity of the 
assay and reducing false positive responses. 
In order to demonstrate the utility of this 3-step approach to the detection of other 
biomolecular species, it was applied to the detection of a DNA and cytokine target. Four 
concentrations of HPV DNA prepared by serial dilution are each undetectable based on 
primary binding to rings functionalized with a 30-mer probe complementary to the HPV 
target (figure 3.7A). Upon the addition of beads conjugated with a separate 30-mer DNA 
probe complementary to the remaining portion of the HPV 46-mer, all 4 concentrations can 
be detected in a concentration-dependent manner. IL-6 is detected using bead-based 
amplification of a sandwich immunoassay (figure. 3.7B). The secondary shift for 10 ng/mL 
IL-6 is amplified ~12x through the use of beads. However, the lower concentration of 0.1 
ng/mL IL-6 (5 pM) is only detectable through the use of bead-based amplification to amplify 
the secondary signal. 
 
3.5 CONCLUSIONS 
In this paper, we demonstrate a three-step immunoassay on a scalable silicon photonic 
biosensing platform that enables a protein antigen to be detected over six orders of magnitude 
of concentration in complex, clinically-relevant sample matrices. While primary binding 
allows detection at higher concentrations, subsequent secondary and tertiary binding events 
significantly lower the LOD. The secondary and tertiary binding also increases the specificity 
of the assay by requiring additional target-specific recognition, allowing discrimination 
against non-specific interferants. Using this approach in a standard addition format, we 
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determined the concentration of CRP in both human serum and plasma across a broad 
dynamic range while avoiding the need for multiple serial dilutions. This methodology, 
which is facilitated by a real-time and modularly multiplexable sensor technology, is 
applicable beyond the detection of CRP as demonstrated using a DNA an cytokine target. 
The generality of this technique should make it useful in multiplexed analyses where analytes 
may differ in concentration by orders of magnitude. 
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3.7 FIGURES 
 
Figure 3.1. Schematic and real-time data plot showing sequential addition of CRP, 
biotinylated secondary antibody, and SA-functionalized beads. The red trace is 10
-1
 µg/mL 
CRP. The blue trace is 10
-3
 µg/mL CRP.  * indicates buffer rinse, and arrows indicate 
solution injection. 
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Figure 3.2. Negative control experiment for 10
-2
 µg/mL CRP sandwich assay with bead 
amplification. The red plot represents the response to 10
-2
 µg/mL CRP (t = 5 min) followed 
by the introduction of 1.6 µg/mL biotin-anti-CRP M701288 (t = 28 min) and subsequent 
signal amplification with 50 µg/mL streptavidin-conjugated beads (t = 46 min). The blue plot 
represents a ring that is first exposed to buffer without any CRP followed by the same 
secondary antibody and bead solutions. No primary, secondary, or bead signal is observed on 
rings not exposed to CRP, which demonstrates no appreciable non-specific binding of 
secondary antibodies or beads. * indicates buffer rinse and the arrows indicate the 
introduction of the identified solutions at the times noted. 
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Figure 3.3. Log-log calibration plot showing the response of the microring resonators to 
varying concentrations of CRP using the three-step assay. Black squares indicate the initial 
slope of the primary binding (right axis), red circles indicate secondary antibody shift, and 
blue triangles indicate bead shift (left axis). Error bars represent 95% CI for n=17-47 rings for 
each concentration. Arrows at top represent overlap of dynamic ranges for each assay 
portion. 
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Figure 3.4. Demonstration of chip-to-chip reproducibility for (A) 10
-1
 µg/mL and (B) 10
-3
 µg 
/mL CRP sandwich assays with subsequent bead-based amplification. Both plots display 8 
representative rings, with 1 ring selected from each of 2 channels on a total of 4 chips for 
each CRP concentration. * indicates buffer rinse and the arrows indicate the introduction of 
the identified solutions at the times noted. All assays were conducted in freshly degassed 10 
mM PBS pH 7.4 + 0.05% Tween-20 with 1.6 µg/mL biotin-anti-CRP M701288 and 50 
µg/mL streptavidin-conjugated beads. Statistics for the 10
-1
 µg/mL and 10
-3
 µg /mL 
reproducibility studies are summarized in Tables 3.1A and 3.1B respectively. 
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A Initial Primary Slope Secondary Shift Bead Shift 
 Δpm/min Δpm Δpm 
Average 3.7  117  369 
St. Dev. (ring-to-ring) 0.7  14  47  
St. Dev. (channel-to-channel) 0.3  8  33  
B Initial Primary Slope Secondary Shift Bead Shift 
 Δpm/min Δpm Δpm 
Average - 0.9  73  
St. Dev. (ring-to-ring) - 1.5  15  
St. Dev. (channel-to-channel) - 1.0  8  
Table 3.1.  Average shifts/initial slopes and standard deviations for (A) 10
-1
 µg/mL and (B) 
10
-3
 µg /mL CRP multi-chip reproducibility study. The ring-to-ring standard deviation is 
calculated from the standard deviation for all rings (n = 80) on all 4 chips tested, while the 
channel-to-channel standard deviation is calculated from the standard deviation of the 
average values for each of 8 channels (2 microfluidic channels/chip). In each case, the ring-
to-ring variability exceeds the channel-to-channel variability, suggesting that the use of 
multiple chips for calibrations and quantitative analyses is satisfactory. It is also worth noting 
that the 0.9 ± 1.5 pm secondary shift for 10
-3
 µg /mL CRP represents a concentration on the 
lower boundary of what can be seen with a simple CRP sandwich assay. Although difficult to 
observe with secondary binding, tertiary binding creates an easily measurable response (73 ± 
15 pm). Thus, in addition to enabling detection at previously impossible levels, beads also are 
important for amplifying small secondary signals. 
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Figure 3.5. Detection of CRP in human serum and plasma samples. All samples are diluted 
1:1000 in buffer except for the CRP-depleted serum, which was diluted 1:100. Error bars 
represent the error in the x-intercept determination used in the standard addition analysis. 
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Figure 3.6. Standard addition plots
5
 used to determine CRP concentrations in 6 human serum 
and plasma samples quantified in figure 3.5. Since CRP levels vary over a wide dynamic 
range, quantitation was performed based on bead shift (A, B), secondary shift (C, D, E), or 
primary initial slope (F). Each plot displays the shift or slope data for an unspiked sample 
dilution plus three standard additions of CRP determined by the magnitude of the unspiked 
sample response. The sample identity, fitting equation, quality of fit, x-intercept, and 
observed CRP concentration are presented for each standard addition experiment shown 
above.  
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 CRP Concentration (µg/mL) 
 Ring Resonator Array CRP ELISA 
CRP-Depleted Serum 0.0031 ± 0.0015 - 
Single-Donor Serum #1 0.12 ± 0.05 0.19 ± 0.08 
Single-Donor Serum #2 0.70 ± 0.57 0.39 ± 0.08 
Single-Donor Plasma 0.67 ± 0.14 2.05 ± 0.22 
Pooled Normal Serum 0.89 ± 0.18 1.45 ± 0.10 
Pooled CRP-Elevated Plasma 58 ± 3 105 ± 11 
Table 3.2. Comparison of ring resonator and enzyme-linked immunosorbent assay (ELISA) 
results for six human serum and plasma samples depicted graphically in figure 3.5. Errors for 
the ring resonator array data represent the error in the x-intercept determination used in the 
standard addition assays (as described above). ELISA errors are the standard deviation of 
triplicate assays run according to the manufacturer’s protocol. All ELISA values were 
measured from samples that were diluted to be within the range of the assay, with a 1:1000 
dilution proving optimal for all but the CRP-elevated plasma which required a 1:40000 
dilution. ELISA failed to detect CRP in the CRP-depleted serum at any dilution tested (1:100, 
1:1000, 1:4000). While ring resonator analysis was in strong agreement with ELISA for most 
of the samples tested, some varied by as much as a factor of 2-3. This variation is typical of 
what is observed when comparing a variety of immunoassays, especially considering 
different dilution factors. Prior analyses of CRP samples that each compared separate 
immunoassay methodologies showed a similar degree of agreement between methods.
6, 7
 
These variations also tend to be more pronounced at higher concentrations where additional 
dilution or use of calibration curve extremes are necessary. 
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Figure 3.7. Bead-based signal amplification universally augments ring resonator signals in 
assays designed for the detection of (A) a 46-mer human papillomavirus (HPV) ssDNA target 
and (B) the cytokine interleukin-6 (IL-6). In (A), 4 concentrations of HPV DNA prepared by 
serial dilution [10 nM (blue), 2 nM (orange), 0.4 nM (red), 0.16 nM (black)] are each 
undetectable based on primary binding (t = 6-36 min). Upon the addition of beads conjugated 
with a separate 30-mer DNA probe complementary to the remaining portion of the HPV 46-
mer (t = 37 min), all 4 concentrations can be detected in a concentration-dependent manner. 
HPV DNA assays were conducted in freshly degassed 10 mM PBS pH 7.4 + 0.05% Tween-
20 with 20 µg/mL HPV probe-conjugated beads. In (B), 10 ng/mL (blue) and 0.1 ng/mL 
(black) IL-6 are detected using bead-based amplification of a sandwich immunoassay. The 
lower concentration of 0.1 ng/mL IL-6 (5 pM) is only detectable through the use of bead-
based amplification to amplify the secondary signal. IL-6 assays were conducted in 10 mM 
PBS pH 7.4 + 0.1 mg/mL BSA with 1 µg/mL biotin anti-IL-6 BAF206 and 50 µg/mL 
streptavidin-conjugated beads. * indicates buffer rinse and arrows indicate the introduction of 
the identified solutions at the times noted. 
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Chapter 4 
 
Magnetically-actuated, bead-enhanced silicon photonic immunoassay 
offering improved speed and limit of detection 
 
Notes and Acknowledgements: 
This chapter is adapted from “Magnetically-actuated, bead enhanced silicon photonic 
immunoassay offering improved speed and limit of detection” (Melinda S. McClellan, Enrique 
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supported by a Robert C. and Carolyn J. Springborn Fellowship from the University of Illinois at 
Urbana-Champaign. 
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4.1 ABSTRACT 
Magnetic actuation has been introduced to an optical immunosensor technology resulting in 
improvements in both rapidity and limit of detection for an assay detecting low concentrations of 
a representative protein biomarker. For purposes of demonstration, an assay was designed for 
monocyte chemotactic protein 1 (MCP-1), a small cytokine which regulates migration and 
infiltration of monocytes and macrophages, and is an emerging biomarker for several diseases 
The immunosensor is based on arrays of highly multiplexed silicon photonic microring 
resonators. A one-step sandwich immunoassay was performed and the signal was further 
enhanced through a tertiary recognition event between biotinylated tracer antibodies and 
streptavidin-coated magnetic beads. By integrating a magnet under the sensor chip, magnetic 
beads were rapidly directed towards the sensor surface resulting in improved assay performance 
metrics. Notably, the time required in the bead binding step was reduced by a factor of 10, 
leading to an overall decrease in assay time from 73 min to 32 min. The magnetically-actuated 
assay also lowered the limit of detection (LOD) for MCP-1 from 200 mL
-1
 down to 80 pg mL
-1
. 
In sum, the addition of magnetic actuation into bead-enhanced sandwich assays on a silicon 
photonic biosensor platform might facilitate improved detection of biomarkers in point-of-care 
diagnostics settings.  
 
4.2 INTRODUCTION 
The detection of protein biomarkers continues to grow in importance as these biomolecules 
are increasingly used as indicators of disease state. In addition to having sufficient sensitivity and 
appropriate limits of detection, diagnostic technologies must also provide results in timeframe 
consistent with the requirements of the setting. Long analysis times often represent a hindrance 
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to the translation of many promising biomarker detection technologies to point-of-care 
applications. For example, many well-established and commercialized biomarker detection 
methods, including plate-based ELISAs, Luminex, and the more recently developed 
ultrasensitive Erenna assay system, each have total assay times of several hours or longer. 
Therefore, there still exists a need for new technologies that can provide relevant analytical 
metrics but with significantly reduced time-to-result.  
Over the past several years, our group has developed a biosensing technology based on 
silicon photonic microring resonators.
1,2
 This technology leverages semiconductor fabrication 
methods to create arrays of sensors (typically 32 or 128 sensor elements) that can be used for 
multiplexed biomarker detection. Each individual microring supports optical resonances, and the 
spectral position of these resonances is sensitive to changes in the local refractive index. When 
functionalized with an analyte-specific capture agent, binding of the target biomolecule at the 
microring surface leads to a resonance shift that can be monitored as a function of time. Both the 
rate and absolute magnitude of the resonance shift can then be utilized to determine the 
concentration of biomarkers within the sample.  
We previously demonstrated the general utility of these sensors for the detection of a range of 
biomolecular targets, including proteins,
3
 nucleic acids,
4
 whole virus particles,
5
 and biotoxins,
6
 in 
both single- and multiplex formats. Additionally, we have shown the ability to quantitate 
biomarker levels from within complex sample matrices such as crude plant extracts,
5
 cell culture 
media,
7,8
 and human body fluids, including serum and plasma,
9
 and cerebrospinal fluid.
10
 
Notably, for detection on complex sample matrices, assay specificity is often increased through 
the use of sandwich assay formats, and the addition of the tracer antibody affords additional 
methods for improving assay performance. Specifically, in several recent studies we have 
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exploited the sandwich assay format to reduce limits of detection by incorporating enzymes or 
beads as labels.
9,10
 
Of particular relevance to this manuscript, the bead based enhancement strategy 
demonstrated both an improvement in limit of detection and an increase in dynamic range, due to 
the incorporation of a 3-step assay format. However, multi-step assay that included the relatively 
slow diffusion of beads to the microring surface necessitated an assay time of ~70 minutes. 
Given that the beads utilized in that assay have magnetic cores, and inspired by related studies on 
a related surface plasmon resonance platforms,
11,12
 we reasoned that the total assay time could be 
significantly decreased by using a magnetic field to draw the beads to the surface. This would 
overcome diffusion-based limitations and minimize the time period needed to achieve the 
maximum resonance shift. 
Monocyte chemotactic protein 1 (MCP-1; also known as CCL2) was chosen as a model 
biomarker for demonstrating the rapid detection of a clinically-relevant target. MCP-1 is a 
cytokine that has been highlighted as a potential marker of sepsis.
13
 Given its acute nature and 
rapid progression, sepsis is a prime example of a clinical presentation that would benefit from 
rapid diagnostics as the rate of survival is strongly correlated with time to therapeutic 
intervention.
14
 Considering just the detection of MCP-1, as one of several potential biomarkers 
for sepsis, commercial ELISA kits feature total assay times of 3+ hours, highlighting the need for 
more rapid diagnostic approaches. 
In this work, we incorporate a magnetic field to actively direct beads down towards the 
microring sensor surface in a sandwich immunoassay for MCP-1. We compare the use of a 
magnetic field versus passive diffusion of the magnetic beads in a standard flow configuration. 
We find that the incorporation of the magnet allowed the assay to be shortened from 74 min to 32 
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min. We also observed that the limit of detection was modestly improved when then magnet was 
employed (190.9 vs. 258.3 pg mL
-1
). These assay improvements, coupled with the multiplexing 
capability of the silicon photonic detection platform, position it as an attractive technology for 
point-of-care biomarker detection. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Materials. Anti-Human MCP-1 (anti-CCL2; catalog number 14-7099), biotinylated 
anti-MCP-1 (anti-CCL2; catalog number 13-7096), and recombinant human protein MCP-1 
(CCL2; catalog number 14-8398) were purchased from eBioscience, San Diego, CA. Mouse IgG 
(catalog number ab37355) was purchased from abcam, Cambridge, MA.  The assay running 
buffer (PBST) was made by reconstituting Dulbecco’s Phosphate Buffered Saline (Sigma, 
catalog number D5773-50L) to include 0.05% Tween20 (Sigma, catalog number P9416-100mL). 
Starting Block (catalog number PI37538) was purchased from Fisher. Glycine (catalog number 
12007-0010) was purchased from Acros (New Jersey). Streptavidin coated magnetic beads with 
~200 nm diameter (catalog number 0.22) were purchased from Ademtech (Pessac, France; 
distributed by Accurate Chemical & Scientific Corp, Westbury, N.Y.). Bis[sulfosuccinimidyl] 
suberate (BS3; catalog number 21585) and 3-aminopropyltriethoxysilane (APTES; catalog 
number 80370) were purchased from Thermo Scientific. Small neodymium magnets measuring 
1/8” x 1/8” x 1/16” and magnetized through thickness were purchased from K & J Magnetics, 
Pipersville, PA (catalog number B221). All other chemicals were purchased from Sigma and used 
as purchased. 
4.3.2 Sensor Fabrication. Sensor chips and read out instrumentation were obtained from 
Genalyte, Inc. (San Diego, CA) and have been described previously.
1,2
 Briefly, arrays of 32-
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individually addressable microring sensors were fabricated into the top layer of silicon-on-
insulator at a commercial-scale silicon foundry (IMEC). Proximal to each microring resonator is 
a linear interrogation waveguide, through which the optical properties of the microring can be 
probed by coupling light through input and output diffractive grating couplers. Post fabrication, 
the entire chip surface is coated with a perfluoropolymer and then photolithography and reactive 
ion etching were used to open annual openings over 24 of the microrings. These microrings 
come into contact with the flowing solution during a detection experiments and the remaining 8 
occluded rings serve as thermal controls. 
In a sensing experiment, sensor chips are loaded into a previously described fluidic cartridge. 
Solutions are then flowed directly across the surface through a microfluidic gasket under the 
control of a syringe pump. The assembly was loaded into the instrumentation and light was 
coupled into the sensor grating coupler from and tunable external cavity laser. Each sensor was 
monitored in a serial fashion as the laser was swept through a 12 nm spectral window with 
resonance wavelength monitored in real-time as a dip in transmittance. 
4.3.3 Sensor Functionalization. Prior to functionalization, sensor chips were briefly 
immersed in acetone (2 min) with gentle swirling to remove a protective photoresist coating on 
the chip surface. Chips were then submerged in 5% APTES in acetone (4 min) followed by 
submersion in acetone (2 min) with gentle swirling and submersion in isopropanol (2 min) with 
gentle swirling. Chips were then dipped briefly in water and blown dry with compressed air or 
nitrogen. Following this 50 μL of a solution of BS3 (2.86 g L-1, in 2 mM acetic acid) was spotted 
by hand onto the chip surface and allowed to sit for 3 minutes. The chip was then blown dry. 
To functionalize with a capture agent solutions, microrings were spotted with either the 
capture antibody (Anti-Human MCP-1, 0.3 mg mL
-1
, in 10 mM PBS with 5% glycerol) or with 
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an off-target control (Mouse IgG, 0.3 mg mL
-1
, in 10 mM PBS with 5% glycerol). Spots of 0.6 
μL were placed over the desired groups of microrings with the aid of a stereoscope and allowed 
to incubate in a humidity chamber for at least one hour. The surface of the chip was then rinsed 
with starting block and stored submerged in in a 1 mL aliquot of starting block at 4 °C until use. 
4.3.4 One-step-sandwich pre-formation. The antigen-tracer antibody complex was formed 
off chip prior to introduction to the sensor by incubating samples (0.4 mL) having various MCP-
1 concentrations with biotinylated tracer antibody (3.22 μL, stock concentration: 500 μg mL-1) 
for 15 minutes prior to microring analysis. 
4.3.5 Magnetic bead exchange procedure. We have found that using freshly prepared 
magnetic bead solutions with carefully controlled bead concentrations is crucial for accurate 
quantitation. Prior to a detection experiment, an aliquot of 10 μL of the magnetic bead stock 
solution was placed in a 1.5 mL microcentrifuge tube. The magnetic beads were separated using 
a magnet and washed once with 100 μL of PBST buffer. The beads were resuspended in 750 μL 
of PBST buffer and absorbance at 286 nm was measured on a Nanodrop instrument. PBST buffer 
was then added to the bead solution to adjust the absorbance to 0.1. The bead solution was 
freshly prepared immediately before each detection experiment. 
4.3.6 Magnet array configuration. For the magnetic field actuation, a chip holder was 
designed that included a removable array of 9 neodymium 1/8 inch diameter x 1/16 inch deep 
round magnets arranged in a 3x3 array with alternating north and south poles facing upwards. 
4.3.7 MCP-1 assay without magnetic enhancement. In the case of the assay without the 
magnetic actuation, the MCP-1 assay was conducted as follows. First, the functionalized sensor 
chip was loaded into the fluidic cartridge with a gasket with containing two side-by-side 
channels. PBST was flowed across the chip (2 min) followed by glycine (3 min), and then PBST 
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(10 min). The one-step sandwich solution was then flowed (10 min) across the chip with 
different MCP-1 concentrations in each channel followed by PBST (2 min). The freshly prepared 
magnetic bead solution was then flowed across the chip for 45 min in the absence of a magnetic 
field. Finally, PBST was flowed for 1 min to allow determination of the final net shift for the 
bead enhancement step. 
4.3.8 MCP-1 assay with magnetic enhancement. The magnetically actuated MCP-1 assay 
was conducted identically to that described above up until the point that the magnetic beads were 
introduced. After the introduction of the bead solution, the magnet array was then physically 
cycled in and out of the cartridge in 10 s intervals for a total of 3 min. Finally, PBST was flowed 
for 1 min to allow determination of the final net shift for the bead enhancement step. 
4.3.9 Data analysis. Shifts in the resonance wavelength were determined by measuring the 
difference in resonance wavelength of the anti-MCP-1-functionalized microrings before the 
introduction of beads and then after the solution was returned to buffer following signal 
enhancement. The shift from off-target mouse IgG-functionalized control microrings was also 
subtracted to account for non-specific adsorption.  
Standard curves were obtained, using OriginPro 9.1.0, plotting the total shift data in respect 
to the MCP-1 concentration and fitting the points to the logistic four-parameter equation, 
𝑓(𝑐) =
𝐴1 − 𝐴2
1 + (
𝑐
𝑐0
)
𝑝 + 𝐴2 
where A1 is the maximum shift variation corresponding to the maximum amount of target, A2 
is the minimum shift variation corresponding to the minimum amount of target, c0 is the center 
of the fit, and p is the power of the fit. Limit of detection (LOD) was estimated as the 
concentration providing the average of the blank plus 3 times the standard deviation of the blank. 
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4.4 RESULTS AND DISCUSSION 
Silicon photonic microring resonators arrays, each having 24 individually addressable 
sensors, were used for the real time monitoring of MCP-1. Microring sensors were 
functionalized to present either specific anti-MCP-1 capture antibodies or mouse IgG control 
antibodies (Figure 4.1a). Prior to the resonance measurements, substrates were loaded into a 
fluidic cartridge (Figure 4.1b) that was modified to allow incorporation of an array of 
neodymium magnets. Solutions containing different concentrations of MCP-1 were pre-
incubated with a biotinylated tracer antibody and then flowed across the substrates through two 
channels that were defined by a laser cut Mylar gasket to assemble the sandwich assay. Freshly 
prepared magnetic bead solutions were then introduced to the flow cell. For magnetically 
actuated bead enhancement, the magnet was cycled in and out of the cartridge to actively drive 
the beads towards the sensor surface, while experiments performed in the absence of the 
magnetic field relied upon passive diffusion of beads to the surface (Figure 4.1c). The flow 
channels were then returned to buffer and the net resonance shift due to the presence of magnetic 
beads was determined. The shift in resonance wavelength was monitored during each step of the 
assay, including sample/tracer binding, and during the bead-based signal enhancement step. 
The primary goal of this study was to determine whether the implementation of a magnetic 
field to actively direct beads towards the microring sensor surface would lead to an improvement 
in assay metrics, specifically time-to-result, by avoiding the time needed for beads to passively 
diffuse to the sensor surface. Figure 4.2a shows the real-time resonance wavelength shifts 
accompanying the binding of magnetic beads, both through magnetic actuation (black trace) and 
passive diffusion (red trace). Using magnetic enhancement we observed a very rapid increase in 
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the total resonance shift allowing the assay to be conducted in a total of 32 minutes. It is notable 
that at 32 minutes into the assay the response from the passive diffusion experiment was 8-fold 
lower than that of the magnetically actuated experiment. A much longer bead incubation (45 
minutes) was needed to record a similar magnitude sensor response, which brought the total 
assay time to 73 minutes. Both of these assay formats are considerably faster than commercial 
available MCP-1 ELISA Kits (e.g., Pierce and R&D Systems). 
In addition to assay rapidity, we also found that the magnetic enhancement strategy led to an 
improved limit of detection. Figure 4.2b shows calibration curves for both the magnetically-
actuated and passive diffusion detection experiments across arrange of MCP-1 concentrations (0 
- 5 ng mL
-1
). For the magnet-based enhancement (black points), the LOD was determined to be 
80 pg mL
-1
. By comparison, after only 32 min total assay time the LOD for the passive diffusion 
experiment (red points) was higher210 pg mL-1. The inset of Figure 4.2b also shows a 
comparison between the 32 min magnet enhancement (black points) and the 73 min passive 
diffusion (blue points) experiments. While these two standard curves are more similar, the 
shortened assay featuring magnetic enhancement again had a lower LOD, with the 73 min assay 
LOD being 180 pg mL
-1
, respectively. Notably, in both comparisons, the 32 minute magnet assay 
had a broader dynamic range than either passive diffusion detection experiment, which would be 
more useful for clinical diagnostic applications. 
 
4.5 CONCLUSIONS 
This work demonstrates the integration of an array of magnets that can improve assay 
performance by actively pulling down magnetic beads onto a silicon photonic microring 
resonator platform. As a model system, we detected the inflammatory biomarker MCP-1 and 
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found that the assay time-to-result can be dramatically reduced by >56% (73 min down to 32 
min) compared to an assay that relied upon passive diffusion alone. We also observed a modest 
improvement in assay LOD, which was lowered to 80 pg mL
-1
, respectively. While this proof-of-
concept study focused on the detection of MCP-1, the methodology could be generally applied to 
any sandwich assay-type assay format for protein or even nucleic acid biomarkers of interest. 
Therefore, this technology could be broadly applied to the detection of other biomarkers of high 
clinical interest where sensitivity and assay time are important considerations, as is the case for 
many point-of-care diagnostic applications. 
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4.7 FIGURES 
 
Figure 4.1. a) Map of the distribution of spotted capture and control antibodies across the 
sensor surface, including thermal control microrings. The chip was divided into two fluidic flow 
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channels. b) Top and side view of the fluidic cartridge components and magnet array. c) 
Comparison between the use of magnetic actuation to pull beads to the sensor surface and 
passive bead diffusion. 
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Figure 4.2. a) Direct comparison of the effect of magnetic actuation on sensor response for 
the detection of MCP-1 in a sandwich immunoassay format on a microring resonator analysis 
75 
 
platform. In both traces a concentration of 5 ng mL
-1
 was detected and the responses are from 
three identical replicates with error bars indicating the standard deviation. The black trace shows 
the rapid increase in resonance shift measured when an array of magnets placed under the 
cartridge is used to actively pull beads to the sensor surface. By comparison, passive diffusion 
alone (red trace) shows a much longer amount is required and that the total resonance shift is still 
smaller when compared to magnetic actuation for the detection of the same concentration of 
MCP-1. b) Calibration curves were constructed based upon the magnetically-actuated and 
passive diffusion enhancement strategies. The main plot compares the two assays at the same 32 
minute total assay time and clearly shows improved performance with magnetic actuation (black 
points) compared to passive diffusion (red points). The inset compares the 32 minute 
magnetically-actuated assay (black points) with the 73 minute passive diffusion experiment (blue 
points) and again shows that the magnetically-actuated detection strategy offers improved limits 
of detection and a wider working range. 
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Chapter 5 
 
Direct comparison between bead-based and enzyme-
based amplification strategies 
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5.1 ABSTRACT 
Previous work has demonstrated the utility of bead-based signal amplification strategies for 
decreasing limit of detection and either expanding dynamic range or decreasing analysis times. 
At the same time as I was exploring these approaches, others in the group were developing an 
enzyme-based amplification scheme. Both approaches proved successful; however, the extent to 
which each method could improve assay performance when directly compared was unclear. This 
chapter discusses a project whose goal was to compare, side-by-side, the qualities of bead-based 
and enzyme-based signal amplification. Using the cytokine IL-2 as a model target, it was 
ultimately determined that the enzyme-based approach would yield better performance and be 
much more amenable to automation. 
 
5.2 INTRODUCTION  
As demonstrated in Chapters 3 and 4 (adapted from Luchansky et al. 2011 and McClellan et 
al. 2014), a signal amplification strategy involving magnetic beads with diameters in the 100s of 
nm range could decrease detection limits and either expand dynamic range or greatly decrease 
analysis times
1,2
. In Luchansky et al. 2011 it was shown, using CRP as a model biomarker, that a 
3-step binding process could be used to quantitate high levels of target at the initial primary 
binding step, medium concentrations at the secondary binding step, and low levels at the tertiary 
bead-binding step. The limit of detection in this study was 30 pg/mL (0.24 pM), and the dynamic 
range spanned six orders of magnitude. Though this was an improvement on previous analyses, 
there were significant drawbacks. The analysis time for this experiment was 70 minutes; 
however, from the binding curves it is evident that the bead-binding step was not approaching 
equilibrium. Even allowing much longer bead binding times did not yield saturated signal at high 
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target concentrations. Additionally, it was observed that it was crucial to the performance of the 
magnetic beads to wash them immediately before use. A delay of even several minutes showed 
declining performance. This, therefore, required extremely precise timing on the part of the 
operator. 
In order to address some of these issues, I developed a method in which bead binding was 
rapidly conducted using a permanent magnet to pull the magnetic beads down to the surface of 
the chip, as shown in Chapter 4 (McClellan et al. 2014). In addition, the primary and biotinylated 
tracer antibody were combined in a single step sandwich format. This resulted in significantly 
lowered analysis time and, by quickly covering the sensor surface with magnetic beads, rapidly 
saturated the biotin sites presented on the sensor. Though this method effectively addressed the 
issue of long time to result from the previous bead-based amplification strategy, the drawback of 
significant user input during analysis could not be circumvented, and in fact was made more 
pronounced as the magnet must be cycled in an out of the instrument by hand. Thus an 
alternative method of signal amplification was sought that could fix these issues. 
During the same time as the bead-based methods were being developed, others in the group 
were working to develop an enzyme-based amplification strategy. This is outlined in Kindt et al. 
2013
3
. Briefly, the streptavidin-coated bead is replaced with a Horseradish peroxidase (HRP) –
conjugated streptavidin. The HRP is then used to catalyze the formation of an insoluble 4-chloro-
1-napthon (4-CNP) precipitate from a 4-chloro-1-napthol (4-CN) substrate. This precipitate coats 
the sensor rings creating a very large, i.e. 1000s of pm, resonance shift, allowing for the 
detection of very low numbers of bound analytes. These two methods were compared using the 
same analyte and experimental conditions in order of facilitate a direct comparison. 
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5.3 MATERIALS AND METHODS 
5.3.1. Materials. PBST buffer is prepared from reconstituted Dulbecco’s phosphate buffered 
saline (Sigma Aldrich) with 0.05% Tween-20. PBST/BSA buffer is prepared from the PBST 
buffer with 0.1 mg/mL bovine serum albumin. IL-2 antigen was purchased from eBioscience 
(14-8029). IL-2 capture antibody was purchased from BD Biosciences (555051); IL-2 detection 
antibody 1 was purchased from BD Biosciences (555040); IL-2 detection antibody 2 was 
purchased from eBioscience (MQ1-17H12); IL-4 capture antibody, used as an off-target control, 
was purchased from eBioscience (8-D4-8). The silane 3-N-((6-(N’-isopropylidene-
hydroazino))nicotinamide)propyltriethoxysilane (HyNic Silane) and succinimidyl-4-
formylbenzamide (S-4FB) were purchased from Solulink. Zeba protein desalt columns were 
purchased form Thermo Scientific. Capture antibodies were modified with Solulink S-4FB 
according to the manufacturer’s protocol. Similarly, detection antibodies were modified with 
Thermo Scientific EZ-Link NHS-PEG4-Biotin following the manufacturer’s protocol. 
Biotinylated tracer antibody solution is prepared by preparing a solution of 1 μg/mL each of two 
biotinylated antibodies in the running buffer of the assay. Streptavidin coated 200 nm magnetic 
beads were purchased from Ademtech. Streptavidin-conjugated horseradish peroxidase (SA-
HRP) was purchased from Thermo Scientific. 4-CN solution is prepared adding 24 μL of 0.3 % 
H2O2 in water to 776 μL of stock 4-CN solution. All other reagents were purchased form 
ThermoFisher and used as received.  
5.3.2. Chip fabrication and functionalization. The sensor chips are functionalized in the 
same manner as previous studies using HyNic silane to install HyNic moieties on the surface of 
the sensor which then form a covalent hydrazone bond with the 4-fB modified capture 
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antibodies. Chips were functionalized with two antibodies, an antibody specific to the antigen 
IL-2 and an off-target biological control antibody specific to IL-4. 
5.3.3. Bead-based amplification. The bead-based assay is carried out in a manner similar to 
that described in for previous bead-base assays. Primary antigen binding is conducted for 20 
minutes, followed by a brief rinse in the PBST running buffer. This is followed by 10 minutes of 
biotinylated tracer antibody solution binding and another brief rinse in PBST. Finally a solution 
of 100 μg/mL freshly exchanged 200 nm diameter magnetic beads is flowed over the chip for 15 
minutes with a final PBST rinse afterwards. 
The bead solution is prepared immediately before use during each run. This is described in 
Chapter 3 with important changes being the increase in bead concentration from 50 to 100 
μg/mL (standardized between runs by adjusting absorbance at 286 nm to 0.15). 
5.3.4. HRP-based amplification. The HRP-amplification assay is conducted according to 
the procedure in Kindt et al. 2013. Briefly, 20 minutes of primary antigen binding is followed by 
a brief rinse in PBST/BSA running buffer and 10 minutes of biotinylated tracer antibody 
solution. This is then followed by a brief rinse in PBST/BSA and 10 minutes of exposure to 2 
μg/mL SA-HRP. This is then followed by another brief rinse in PBST/BSA and 25 minutes of 
exposure to freshly prepared 4-CN solution. Finally, a last rinse in running buffer allows for 
quantitation of the total shift without the bulk RI shift from the 4-CN solution. 
5.3.5. Data workup. Total shifts were quantitated by subtracting the resonance shift before 
amplification step from the resonance shift after the signal amplification step, whether bead- or 
HRP-based. The assay was completed on 3 identical chips and the average and standard 
deviations of on- and off-target were calculated and compared. 
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5.4 RESULTS AND DISCUSSION 
A direct comparison between bead-based and enzyme-based enhancement strategies was 
conducted using the interleukin IL-2 as a model target. This target as previously been explored 
by Luchansky et al. in an antibody sandwich format and Kindt et al. in an enzyme-enhanced 
method
3,4
. These studies demonstrated limits of detection of respectively 100 pg/mL and 1 
pg/mL (6.5 pM and 65 fM). In this study, our primary goals were to explore the relative 
enhancement in signal between bead- and enzyme-enhancement, paying particular attention not 
only to the on-target signal, but to the off target signal, standard deviations, and ease of 
automation as well. 
Figure 5.1 shows the bead binding step following 1.5 ng/mL IL-2 and biotinylated tracer 
antibody mix for 12 on-target and 12 off-target sensors across 3 chips. Figure 5.2 shows the total 
shifts of the on- and off-target sensors with their corresponding standard deviations. Figures 5.3 
and 5.4 show the corresponding data for the enzyme-enhanced signals. In addition to the 
obviously much higher total shifts obtained using the enzyme-enhanced method, several qualities 
stand out as distinguishing the two approaches. As is clearly evident, the standard deviation of 
the bead-enhanced on-target signal is over 40% whereas the enzyme-enhanced is 8%. This high 
ring-to-ring variability in the bead signals is something that has been observed with some 
consistency across targets. It can be minimized by carefully controlling the bead concentration 
and by using freshly washed bead solution; however, even with these procedures, the variation 
exceeds that of other assay formats. In contrast, the enzyme-enhanced signal shows relatively 
low ring-to-ring variability, and preliminary studies with piezoelectric spotted chips (employed 
and discussed in chapter 6) suggest that automated capture antibody spotting can further reduce 
ring-to-ring variability. 
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Of concern with any signal enhancement technique is the extent to which the background is 
elevated along with the specific signal. In comparing the bead-based and enzyme-based results 
presented here, it can be seen that the relative level of the background signal for the beads is 
significantly higher, at 7%, than for the enzyme-enhanced, at 1%. This increased background 
signal of beads relative to enzyme is most likely due to non-specific binding of the beads 
themselves to the sensor surface. Qualitative observations have shown that changing the capture 
agent between antibodies and DNA or changing the chip blocking procedures can drastically 
change this background signal. Therefore, it may be possible to engineer an assay that does not 
suffer from this background signal. However, the enzyme-based enhancement method does not 
appear to suffer from these drawbacks. 
In addition to the above described benefits of enzyme-based signal enhancement over bead-
based, the newest generation of instrumentation incorporates an automated fluidic system which 
greatly decreases the user input needed for running the analyses and should increase precision. 
The enzyme-based method is readily amenable to this automation; however, this is not true for 
the bead-based method due to the beads settling out of solution and the necessity of washing the 
beads immediately prior to use. 
The single benefit that the bead-based enhancement method offers over the enzyme-based 
enhancement method is the opportunity for sample clean-up and pre-concentration. Many others 
have shown the ability to coat magnetic beads with a capture agent (i.e. the tracer antibody) and 
use them for pre-capture of the analyte
5-7
. This allows the matrix to be washed away from the 
analyte and for the analyte-coated beads to be re-suspended in clean running buffer. This reduces 
the non-specific background frequently encountered in complex matrices and, if re-suspended in 
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a smaller volume, allows for concentration of the analyte. However, it is yet to be seen if, on our 
platform, these benefits would surpass those of the enzyme-based approach. 
 
5.5 CONCLUSIONS 
A direct comparison between bead-based and enzyme-based amplification strategies was 
conducted. With greater signal enhancement, lower sensor variability, and lower relative 
background levels, the enzyme-based method proved to be far more effective. For this reason, 
further studies, especially those involving automated fluidics, will make use of this signal 
enhancement method. 
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5.7 FIGURES 
 
Figure 5.1. Graph showing the response of IL-2 functionalized (black) and IL-4 functionalized 
(red) microrings to streptavidin coated magnetic beads after 1.5 ng/mL IL-2 and 1 μg/mL each of 
two biotinylated tracer antibodies. 
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Figure 5.2. Graph showing the total bead amplification shifts for on- and off-target sensors 
following an assay of 1.5 ng/mL IL-2. Error bars represent standard deviations of n=12 
measurements. 
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Figure 5.3. Graph showing the 4-CN response of IL-2 functionalized (black) and IL-4 
functionalized (red) microrings after exposure to 1.5 ng/mL IL-2 followed by 1 μg/mL each of 
two biotinylated tracer antibodies, and 2 μg/mL SA-HRP. 
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Figure 5.4. Graph showing the total HRP-based amplification shifts for on- and off-target 
sensors following an assay of 1.5 ng/mL IL-2. Error bars represent standard deviations of n=11 
measurements for the on-target sensors and n=12 measurements for the off-target sensors. 
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Chapter 6 
 
Development of a multiplexed protein biomarker panel for 
discrimination of liver disease states 
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6.1 ABSTRACT 
Liver cancer is a leading cause of cancer death worldwide with hepatocellular carcinoma 
(HCC) comprising the majority of cases. Despite the FDA approval of alpha-fetoprotein as a 
clinical biomarker for HCC, distinguishing HCC from cirrhosis remains difficult. In this work, 
we show the initial development of a panel consisting of 5 biomarkers used for the diagnosis of 
HCC and distinguishing it from other liver disease states. Initial characterization of the assay in 
buffer is described with LODs well below 1 ng/mL suggested. Additionally, first attempts at 
detection in human plasma are presented with results that indicate the ability to overcome the 
complications of the complex matrix. Finally, a first comparison between the serum of a liver 
cancer patient and a pooled normal serum is discussed. 
 
6.2 INTRODUCTION  
Primary liver cancer is the 6
th
 most frequently diagnosed neoplasm and the 3
rd
 leading cause 
of cancer-related deaths worldwide, causing about 600,000 deaths annually
1
. In the vast majority 
(70%-85%) of cases the cause is hepatocellular carcinoma (HCC). HCC is usually preceded by 
cirrhosis, thus it is not surprising that the risk factors for HCC include the frequent causes of 
liver cirrhosis. These are primarily hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infection, though environmental and genetic risk factors do play a role in HCC risk. Worldwide 
it is estimated that 50%-80% of HCC cases arise from HBV infection and 10%-25% arise from 
HCV infection
1
. As such, the incidence of HCC is much higher in parts of the world where HBV 
incidence is greater, with HBV playing a comparatively lower role in HCC incidence in 
countries such as the United States and Japan where HCV and alcoholic cirrhosis become more 
important risk factors. 
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Currently, patients deemed high-risk undergo routine monitoring for the development of 
HCC. Diagnosis and monitoring methods for HCC include serum alpha-fetoprotein (AFP) levels, 
liver ultrasound scans, CT, and MRI; however, none of these methods provide sufficient 
sensitivity and specificity for the detection of HCC over the background liver disease
2
. 
Interestingly, though widely used for screening, there is a lack of quality studies regarding the 
utility of AFP as a clinical biomarker, and best estimates indicate it to be of only limited value
3
. 
Taken in conjunction with other diagnostic methods, the sensitivity or specificity of APF levels 
may be increased to a small degree
2
. 
In this project we are attempting to create a clinically useful diagnostic tool for monitoring 
patients with chronic liver disease for the development of HCC using a multiplexed biomarker 
panel. Additionally, this panel may prove helpful for the monitoring of HCC patients both during 
and after treatment and for pre-screening of HCC patients for recurrence potential prior to liver 
transplant. In collaboration with Dr. Lewis R. Roberts from The Mayo Clinic, we have chosen a 
panel of 5 biomarkers: alpha-fetoprotein (AFP), Cancer antigen 125 (CA-125), Cancer antigen 
19-9 (CA 19-9), carcinoembryonic antigen (CEA), and osteopontin (OPN). These proteins were 
chosen based on their potential as useful biomarkers, and because previous work in our group 
has shown the ability to detect these 5 proteins side-by-side with sufficient limits of detection 
and limited cross-reactivity
4
. 
AFP is currently used as a biomarker for the diagnosis of HCC, with cutoff levels at 50 to 
200 ng/mL in serum
2,5,6
. CA-125 is traditionally used as a biomarker for ovarian cancer; 
however, it has been detected in the ascetic fluid and, to somewhat lower concentrations, the 
serum of patients with both liver cirrhosis and liver cancer
5,7-9
. It appears to be more indicative of 
the presence or absence of ascites than to any one disease state. CA 19-9 is a carbohydrate 
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biomarker used for the monitoring of pancreatic cancer
5,10
. Serum levels are frequently elevated 
in patients with chronic viral hepatitis infections, but are not specific for cancer
11
. CEA is 
typically found in bowel cancers, but has been shown to be elevated in more than 70% of all 
cancers
5,10
. Osteopontin levels are elevated in a number of cancers including lung, breast, 
colorectal, stomach, and ovarian. It has been shown to be elevated in HCC with a suggested 
cutoff value of 128.5 ng/mL and is associated with vascular invasion and advanced tumor 
grade
12-15
. Additionally, plasma levels appear to be correlated more closely with tumor number 
than with tumor size. 
Alone, each of these biomarkers each present confounding issues which make them of little 
or no utility in HCC diagnosis and monitoring; however, it is our hope that simultaneous analysis 
of these markers will overcome the limitations that any single marker presents. 
The microring resonator sensor chips were designed to contain 6 capture antibodies, 5 which 
are specific to the biomarkers of interest and one mouse IgG control (figure 6.1a). These are 
analyzed simultaneously from a standard or sample containing all targets (figure 6.1b). In order 
to achieve low limits of detection which may be necessary for clinical application, a signal 
enhancement will almost certainly be necessary. Due to the superior limits of detection 
demonstrated in previous studies and the ability to use integrated fluidics, the horseradish 
peroxidase (HRP)-based enhancement method has been chosen for this application. A schematic 
of this approach is shown in figure 6.1c. 
 
6.3 MATERIALS AND METHODS 
6.3.1. Materials. PBST/BSA buffer is composed of reconstituted Dulbecco’s phosphate 
buffered saline (Sigma product number D5773-50L) with 0.05% Tween-20 (Sigma product 
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number P9416-100ML) and 0.1 mg/mL bovine serum albumin (Sigma product number A2153-
100a). Starting block is purchased from Fisher (product number PI37538). Proteins including 
antigens and both capture and tracer antibodies were purchased from a variety of sources 
summarized in Table 6.1. Tracer antibodies are biotinylated following the manufacturer 
recommendations using the Pierce EZ-Link NHS-Biotin linker kit (Thermo Fisher product 
number 20217). Tracer antibody cocktail is composed of 1 μg/mL of each biotinylated tracer 
antibody. Horseradish peroxidase conjugated streptavidin (SA-HRP) is purchased from Thermo 
Fisher (product number PI21130), and diluted to 1 μg/mL immediately before use. The 1-step 4-
CN solution is purchased from Thermo Fisher (product number 34012). Pooled normal serum 
was purchased from Innovative Research (Novi, MI; product number IPLA-SERAB lot 14285). 
Liver cancer serum was purchased from Innovative Research (Novi, MI; lot 63184A5) and 
stored at -80 C until use. All other reagents were purchased from Sigma and used as received. 
6.3.2. Sensor Fabrication and Functionalization. Sensor chips are fabricated as described 
in previous chapters. Notably, these experiments were conducted on the newer Maverick 
instrumentation, which uses chips containing 132 individual sensors, 128 of which are available 
for functionalization with the remaining 4 used as thermal controls. This instrumentation is 
described in section 1.6. 
Sensor chips are spotted using a piezoelectric spotter with the 6 capture probes by Genalyte 
(San Diego) using the APTES/BS3 method described earlier (section 1.3). Each chip contains 6 
groups of 4 sensors for each analyte and 2 groups for the control at concentrations of 250 and 
500 μg/mL. Figure 6.1a shows a diagram of the spotted chips. 
6.3.3. Experimental Protocol. Chips are loaded into a fluidic cartridge containing a single 
channel that spans all sensors. Experiments are then run by establishing flow with PBST/BSA 
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buffer at 30 μL/min for 3 minutes then flowing across solutions at 20 μL/min in the following 
order: PBST/BSA for 8 minutes, 50% starting block in PBST/BSA for 20 minutes, PBST/BSA 
for 10 minutes, sample solution for 20 minutes, PBST/BSA for 2 minutes, tracer antibody 
cocktail for 10 minutes, PBST/BSA for 2 minutes, SA-HRP solution for 10 minutes, PBST/BSA 
for 2 minutes, 1-step 4-CN solution for 25 minutes, and PBST/BSA for 10 minutes. Following 
data collection, a 10% bleach solution is flowed across the chip and through all tubing for 10 
minutes in order to sterilize anything that may have come into contact with BSL-2 materials. 
6.3.4. Data Analysis. The average response from the mouse IgG biological control rings is 
subtracted from all the sensor rings to account for non-specific binding. Total shift for each type 
of capture probe is calculated by subtracting the average shift before the 1-step 4-CN solution 
from the average shift after the return to buffer. Calibration curves are generated by plotting total 
shift (in Δpm) vs. time and fitting the points to a logistic function (described in section 6.4). 
Table 6.3 shows the resulting fitting parameters and adjusted R-squared. Initial studies 
determined that a spotting concentration of 500 μg/mL gave a slightly higher sensor response 
than lower spotting concentrations in almost all cases. For this reason, quantitation was 
performed using those sensors that were functionalized with the higher concentration. 
  
6.4 RESULTS AND DISCUSSION 
Initial studies sought to characterize sensor performance in a buffer system. Standards were 
created which were mixtures of the five proteins of interest at varying concentrations ranging 
from 1 ng/mL (or U/mL) to 100 ng/mL (or U/mL). Table 6.2 shows the exact composition of 
each of the 5 standards. Simultaneous quantitation of the five biomarkers yielded the calibration 
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curves presented in figure 6.2. After correction to the biological control sensors to account for 
non-specific binding, the data was fit to a logistic function, 
𝑓(𝑐) =
𝐴1 − 𝐴2
1 + (
𝑐
𝑐0
)
𝑝 + 𝐴2 
Where A1 is the initial value limit, A2 is the final value limit, c is the center of the fit, and p is the 
power of the fit. 
Of the five calibration plots, four, AFP, OPN, CA 125, and CA 19-9, show good fits. The 
remaining protein, CEA shows a higher initial value limit, suggesting a high background 
interference. As these were preliminary studies and chips were scarce, these results have yet to 
be duplicated. The cross-reactivity studies completed by Adam Washburn and by myself showed 
no appreciable reactivity to the other proteins of interest, so the origin of this background is still 
not determined; however it was not observed in previous studies using this suite of proteins. I 
expect that this phenomenon arises from an error in the assay execution and that it will resolve 
itself after further studies. It is clear from the remaining plots that a concentration of 1 ng/mL (or 
1 U/mL) is readily distinguishable from zero, and there is a good deal of room below this 
response for detection of lower concentrations. 
Following sensor characterization in buffer systems, the performance on actual human 
samples was investigated. First, pooled normal serum diluted to 33% with running buffer was 
analyzed to assess the extent to which matrix effects would obscure the signal from the 
biomarkers of interest. A series of matrix spikes with each of the five targets was prepared in the 
same serum sample. The difference in the measured concentration was compared to the prepared 
concentration in figure 6.3. The line at 45° marks the point where the additional measured 
concentration is exactly equal to the spike as prepared; above this line indicates where a greater 
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than expected increase in concentration was measured; below this line indicates where a lower 
than expected increase in concentration was measured. It is not surprising to see that the presence 
of the serum depresses the signal from the matrix spike. This could be due to a simple blocking 
of the sensor binding sites by the excess protein in the serum, by some complexation of the 
spiked targets by something present in the serum, or by off target primary binding that does not 
respond to the tracer antibody. Of interest is the fact that the percent recovery of the matrix 
spikes is constant over the several concentrations of spiked protein, in other words the same 
fraction of spiked target was lost regardless of the amount of target added to the sample. This 
fraction does, however, vary between targets. Future studies will need to spend some time 
focusing on how best to eliminate or compensate for this signal suppression in order to be 
confident of correct quantitation in real samples.  
A final study sought to show a measurement of the five biomarkers in a sample from a 
patient with liver cancer (run at a 10% dilution with running buffer) and compare those values to 
the values in a pooled normal serum sample (run at a 33% dilution with running buffer). Figure 
6.4 shows the results from this study both in terms of absolute concentrations (a) and relative 
change (b). Between normal serum and that of a liver cancer patient, AFP, CEA, and OPN are 
clearly elevated, CA 19-9 is equal between the two samples, and CA 125 is significantly lower in 
the liver cancer patient. It is well-documented that AFP is elevated in the serum of patients with 
liver cancer, and it is currently used in the clinic for diagnosis. Reports also demonstrate that 
OPN is also elevated in liver cancer patients. Therefore, we expected to see both of these 
proteins elevated with respect to normal serum. Though no data currently exists in the literature 
regarding CEA levels in liver cancer, it is elevated in a number of cancers; thus it is not 
surprising to see it elevated here. The lower signal from CA 125, which does not tract with 
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cancer state or stage, may reflect the absence of ascites in the patient or may be an artifact due to 
the long storage time of this sample. This single result is by no means proof of a useful 
biomarker panel, but is extremely encouraging for future studies involving a larger cohort of 
patient samples. 
 
6.5 CONCLUSIONS 
This study is still very much in the preliminary stages; however, it shows great promise. 
Calibration of the sensors in buffer indicates that limits of detection significantly lower than 1 
ng/mL (or U/mL) may be achievable; in line with demonstrations in other systems. Matrix effect 
studies have shown that there is indeed some interference when moving from buffer systems into 
complex matrices; however, matrix spike studies give some promising indication that it may be 
possible to overcome this issue. Most excitingly, comparing serum from a liver cancer patient to 
pooled normal serum, even in these early stages of the assay development, show results 
consistent with literature reports. 
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6.7 FIGURES AND TABLES 
 
Figure 6.1. a) Diagram showing the locations of specific spotted capture probes for the 6-
plex sensor chips. Groups of 4 rings are spotted simultaneously with 6 redundant groups for each 
target and 2 redundant groups for the control. b) Example of HRP amplification step after 
incubation with 1 ng/mL AFP (green), 50 U/mL CA 125 (red), 50 U/mL CA 19-9 (blue), 50 
ng/mL CEA (black), and 100 ng/mL OPN (magenta) followed by the tracer antibody cocktail 
and SA-HRP solution. c) Schematic showing the binding of a target followed by the HRP-based 
signal enhancement. Part c is adapted with permission from Kindt, J. T., Luchansky, M. S., Qavi, 
A. J., Lee, S.-H. & Bailey, R. C. Subpicogram Per Milliliter Detection of Interleukins Using 
Silicon Photonic Microring Resonators and an Enzymatic Signal Enhancement Strategy. 
Analytical Chemistry 85, 10653-10657, doi:10.1021/ac402972d (2013)
16
. Copyright 2013 
American Chemical Society. 
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  AFP CA 125 CA 19-9 CEA OPN 
Mouse 
IgG 
Antigen 
30-AA06 30-AC21 30-AC14 30-AC32 30R-AO008 
- 
Fitzgerald Fitzgerald Fitzgerald Fitzgerald Fitzgerald 
Capture 
Antibody 
MAM01-301 
LS-
B52464/41630 
10-CA19A MAM02-009 M66102M ab37355 
Meridian 
Life Science 
LifeSpan 
Biosciences 
Fitzgerald 
Meridian 
Life Science 
Meridian 
Life Science 
Abcam 
Detection 
Antibody 
M01254M 10-C02F 10-CA19B MAM02-008 M66103M 
- Meridian 
Life Science 
Fitzgerald Fitzgerald 
Meridian 
Life Science 
Meridian 
Life Science 
 
Table 6.1. Catalog numbers and vendors for all protein reagents. 
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Standard 
# 
[AFP] [CA 125] [CA 19-9] [CEA] [OPN] 
ng/mL U/mL U/mL ng/mL ng/mL 
blank 0 0 0 0 0 
1 5 125 10 10 10 
2 10 5 100 1 1 
3 1 50 50 50 100 
4 100 10 5 5 5 
5 50 100 1 100 50 
 
Table 6.2. Composition of all standard solutions used for generating a calibration curve for the 5 
biomarkers.  
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Figure 6.2. Five calibration curves showing total shift of the 4-CN step as a function of 
target concentration for each target. Curves are fit to a logistic function. Error bars represent the 
standard deviation of the sensor rings. 
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AFP CA 125 
CA 19-
9 CEA OPN 
A1 27.68 1.30 -10.95 3831.12 100.76 
A2 7116.92 8044.08 4559.05 8512.78 11066.78 
c0 67.05 98.05 99.40 32.20 18.80 
p 1.08 1.00 1.07 3.00 1.04 
Adj. R-squared 0.99832 0.99775 0.99493 - 0.99640 
 
Table 6.3. Fitting parameters and adjusted R-squared from all 5 calibration curves in figure 6.2. 
Note: CEA does not have an adjusted R-squared due to it having too few points for reliable 
fitting.  
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Figure 6.3 Measured concentration of each target vs. prepared concentration of matrix spikes 
in a pooled normal serum sample. The black line is a y=x and denotes a perfect recovery of the 
matrix spike. Green squares represent AFP; red circles represent CA 125; blue right-side-up 
triangles represent CA 19-9; black upside-down triangles represent CEA; magnenta diamonds 
represent OPN. Error bars represent the standard deviation of the sensor rings. 
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Figure 6.4. Comparison between pooled normal serum (black) and liver cancer serum (red) 
biomarker levels. Graph (a) shows the absolute concentration and graph (b) shows the relative 
change with respect to the pooled normal sample. Error bars represent the standard deviation of 
the sensor rings. 
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Chapter 7 
 
Future Directions 
 
7.1 MAGNETIC BEADS FOR SAMPLE PURIFICATION AND CONCENTRATION 
Chapters 3-5 discussed the development and application of bead-based signal enhancement 
for providing lower limits of detection and either expanded dynamic range or reduced assay 
time. In chapter 5, it was ultimately determined that the enzyme-based enhancement method 
provided better limits of detection and was more amenable to automation, thus making it the 
scheme of choice for future studies. However, we have yet to address an application of beads that 
may provide benefits which overcome the drawbacks relative to the enzyme-based method: 
sample purification and concentration. 
Current methods employed by our group for bead-based signal enhancement follow a 
protocol in which the analyte is first captured on-chip and subsequent steps build-up the complex 
on the surface using biotinylated tracer antibodies and streptavidin coated magnetic beads. 
However, it is conceivable that this complex could be built on the bead in solution before being 
captured on-chip. First, the magnetic bead would be coated with the tracer antibody. These 
antibody-coated beads would be incubated with a complex sample, allowing for 3D diffusion to 
aide in capture. The beads could then be washed to remove the interfering species from the 
matrix and the beads resuspended in simple buffer before running. By suspending in a smaller 
volume than the original sample, the analytes are effectively concentrated. Allowing the beads to 
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then bind to the surface of the sensors, perhaps in conjunction with magnetic pull-down of the 
beads, would complete signal enhancement in a single step with limited matrix interference. 
Several group members, including myself, have made attempts at employing this method. 
The major stumbling block seems to be conjugating antibody capture agents to the beads. I have 
attempted to use several conjugation techniques including using silane chemistry on silica 
particles, commercial bead conjugation kits, and streptavidin-biotin binding. Simply coating the 
biotinylated tracer antibody on the surface of the streptavidin-coated beads should be a 
straightforward procedure. The likely root of the poor performance we observe is the bridging of 
beads by antibodies which have multiple biotin sites, making large bead aggregates which then 
have more difficulty presenting binding sites for the antigen and more difficulty binding to the 
sensor surface. This suspicion is backed by the relatively good performance we observe when 
using beads conjugated with nucleic acid strands, purchased singly biotinylated, and when 
conjugating antibodies which we under-biotinylate (i.e. in which the majority of antibodies 
contain 0 or 1 biotin moiety instead of the standard 2 or 3). Though this latter method would 
work well, a great deal of protein is wasted as it cannot be captured by the beads and is lost in 
washing steps. It may be interesting to make use of the fact that nucleic acid sequences can be 
purchased with a single biotin site by using aptamers, instead of antibodies, as the tracer capture 
agent. 
In whatever manner it is eventually implemented, I believe that this sample purification 
aspect of bead usage is the only remaining area where bead-based signal enhancement has an 
appreciable future for applications on the microring resonator platform. 
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7.2 MULTIPLEXED BIOMARKER PANEL FOR LIVER DISEASE DIAGNOSTICS 
7.2.1. Overview. As discussed in detail in chapter 6, initial studies have been completed into 
the development of a multiplex biomarker assay for the discrimination of liver disease states. I 
have proven that it is possible to simultaneously assay alpha-fetoprotein (AFP), cancer antigen 
125 (CA 125), cancer antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), and 
osteopontin (OPN) while using a control antibody to correct for the effects of non-specific 
binding. I have generated calibration curves in buffer and used them to quantitate the 5 
biomarkers in serum both from a liver cancer patient and pooled normal sample. A comparison 
between the pooled normal serum and liver cancer serum show results consistent with 
expectations from literature reports. Additionally, investigations into matrix effects show 
promise for being able to either eliminate or compensate for matrix effects. For the future of this 
project I see 3 major areas for further investigation: generate complete calibration curves for 
each of the 5 targets to be used for quantitation, complete investigations into serum matrix 
effects to decide how to overcome the challenges presented by a complex matrix, and analyze a 
large number of patient samples in order to be able to draw biologically relevant conclusions 
about the applicability of this assay for diagnostics. 
7.2.2. Complete calibration curves. The first step in moving forward with the development 
of this assay should be the generation of complete calibration curves for each of the targets and 
the optimization of the limits of detection. Initial attempts at generating calibration curves used 
concentrations from 1 ng/mL (or U/mL) to 100 ng/mL (or U/mL) based upon the limit of 
detection demonstrated by previous studies in our group
1
. However, it is clearly evident that 
using the HRP-enhanced method will yield much lower limits of detection. It is likely, given 
demonstrated limits of detection using HRP-based signal enhancement on other target systems, 
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that we will be able to quantitate concentrations down to at least 10s of pg/mL (or U/mL). Thus, 
an initial starting point for standards should be 0.5 to 1 pg/mL (or U/mL) and should span at least 
5 orders of magnitude. Once these calibration curves have been, it will be possible to determine 
an absolute limit of detection for the assay. 
A potential challenge here may be the contamination of standards of some biomarkers with 
others. Washburn et al. has shown that in standards derived from human materials (such as CA 
125 and CA 19-9), incomplete purification may leave behind traces of other targets. With our 
sensitivity, these traces are likely to be readily observable and may make determining the 
absolute concentrations in our standard mixes difficult. Additionally, cross-reactivity between 
antigens and antibodies of different targets could create background signals that further 
complicate quantitation. As in this previous work, a careful analysis of the individual standards 
and tracer antibodies at high concentrations should bring these issues to light. 
7.2.3. Matrix effects in human serum. Initial investigations into matrix effects showed a 
depression of signal from targets spiked into 33% pooled normal serum. This signal suppression 
is not surprising; however, a standardized method of either eliminating it, likely through dilution 
of the serum with running buffer, or compensating for it will need to be developed. A simple 
approach is to dilute the serum samples to an extent that any possible interferants species in the 
sample are at such low concentration that they do not hinder, to an appreciable extent, the 
quantitation. However, this method also dilutes the analyte of interest, requiring lower limits of 
detection to achieve clinically relevant results. With the HRP-enhanced method, there is a good 
chance that our limits of detection will be sufficiently low to allow for this method to be 
employed. 
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The observation regarding constant percent recovery of matrix spikes regardless of 
concentration suggests an alternative method. It may be possible to use this property to create 
some sort of correction factor on the determined concentration. Perhaps running side-by-side 
analyses of a serum sample and the same sample with spiked target would allow for a 
multiplicative factor to be determined on a case by case basis. This method has the additional 
benefit of eliminating some of the inherent person-to-person variation usually observed in 
biological studies. 
7.2.4. Clinical studies using a cohort of patient samples. The final step in this project will 
be analyzing a number of patient samples in order to determine if this panel of biomarkers does 
indeed have diagnostic capabilities. Our collaborators have already sent 20 blinded serum 
samples from patients from a number of different disease states including healthy, cirrhosis, and 
hepatocellular carcinoma. Once we have developed a fully characterized analysis, it should 
simply be a matter of running the samples using the automated fluidics and performing statistical 
analysis on the samples. It is hoped that we will see some correlation between the levels of the 5 
biomarkers and the disease state of the patient. 
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Appendix A 
 
Controlling multivalent interactions and bead binding frequency by 
modulating bead surface coverage 
 
Notes and Acknowledgments: 
This work was funded by the National Science Foundation. I acknowledge Adam L. 
Washburn for help with assay design and fluorescence measurements. 
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A.1 DISCUSSION 
In the course of bead-based studies, it was observed that under certain conditions it is 
possible to observe the binding of single beads appearing as stepwise jumps in resonance shift. 
This work was part of a project attempting to use this stochastic detection of beads for 
quantitation based on counting binding and release events. In order to use statistics to gain 
meaningful results from this information, however, it was necessary to make sure that the beads 
were bound to the surface by a single interaction. In addition, release events had never een 
observed despite changing solutions to attempt to destabilize the interactions or when increasing 
flow rates to attempt to use sheer force to remove bound beads. Therefore, it was also hoped that 
limiting binding to monovalent interactions would allow us to finally see release events. 
For initial explorations into this area, we attempted to control the valency of interactions 
between beads and the microring by controlling the density of two different DNA probes on the 
beads. First, we mixed two types of biotinylated DNA strands, one of which was fluorescently 
tagged, with streptavidin-coated magnetic beads to tune of the percentage of each strand on the 
surface of the beads. Fluorescence studies did indeed show that higher ratios of fluorescent DNA 
strands resulted in greater fluorescence (Figure A.3). Below 10% fluorescent DNA there is little 
appreciable difference in the measured fluorescence; however, it should be noted that the 
scattering caused by the suspended beads in solution may make discriminating between small 
differences in fluorescence difficult. 
We then analyzed the same ratios utilizing a DNA strand complementary to a capture probe 
immobilized on the microring sensor surface to determine whether different on rates of bead 
binding to the sensor surface could be observed. Figure A.1 shows the workflow for creating 
beads with varying mixtures of DNA strands on their surface. Figure A.2 shows a schematic of 
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monovalent vs. multivalent binding of the mixed DNA strands. When analyzed on the microring 
resonator instrumentation, it was observed that the on rates did differ between various 
percentages of DNA complementary to the surface capture probe (Figure A.4). The highest rate 
was observed for the bead with 100% complementary strand; intermediate binding was observed 
for 50% and 10% complementary strands; little or no binding was observed for beads with 1% or 
less of complementary strand. The relatively high background binding of beads with no 
complementary strand is a phenomenon we observed in all early studies with beads, and further 
optimization of blocking steps has essentially eliminated this issue. 
Despite these successes, we were ultimately unsuccessful in generating release events, and 
the investigations moved in a more productive direction. 
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A.2 FIGURES 
 
Figure A.1. Schematic showing the generation of magnetic beads coated with differing ratios 
of two DNA strands. Blue DNA strands represent the complement sequences and red represents 
the filler strand. 
  
Filler Compliment 
and Filler
Compliment
Biotinylated DNA
Streptavidin Coated
Magnetic Nanoparticles
Magnetic Nanoparticle/DNA conjugates and free excess DNA
Magnetic Separation
Magnetic Nanoparticle/DNA conjugates
116 
 
 
Figure A.2. Schematic showing monovalent vs. multivalent binding of beads to the surface 
based on the density of complementary strands on the bead surface. 
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Figure A.3. Graph of normalized fluorescence intensity of beads with increasing percentage 
of fluorescent DNA strands. 
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Figure A.4. Bead binding to the surface of the microring resonator sensor chip. Higher 
percentages of complement DNA on the bead results in a higher number of beads bound to the 
surface during the same time. 
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Appendix B 
 
COMSOL modeling of fluid flow in the microring resonator fluidic 
cartridge 
 
Notes and Acknowledgments: 
This work was funded by the National Science Foundation. I would like to acknowledge the 
Imaging Technology Group at the Beckman Institute for the use of the COMSOL software. 
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B.1 DISCUSSION 
During the course of our investigations into bead-based application on the microring 
resonator system, we became curious about the flow profile abouve the sensor chips. We 
primarily wanted to see the fluid velocity in the vicinity of the ring surface to determine the 
magnitude of the sheer force on bound beads. We also wanted to see whether the recessed 
annular opening in the perfluoropolymer cladding layer or the raised microring itself would 
cause turbulence in the fluid flow. 
Below I present the results of some basic simulations using COMSOL multiphysics software 
showing the fluid flow over the microring resonator. These simulations were done both in a 2-
dimensional and 3-dimensional space, with the 2-dimensional model including turbulence 
factors.  
121 
 
B.2 FIGURES 
 
 
 
Figure B.1. 2-dimensional simulation, including turbulence, of fluid velocity (µm/s) over a 
cross-section of the microring. The progression from top to bottom shows an increase in the 
range of velocities visualized (top 0-10 µm/s, middle 0-40 µm/s, bottom 0-100 µm/s). Red 
indicates high velocity; blue indicates low velocity.  
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Figure B.2. 3-dimensional simulation of fluid velocity over the microring with slices in each 
2-dimensional plane. Red indicates high velocity/ blue indicates low velocity. The top image 
shows 0-0.01 m/s; the bottom two images show 0-100 µm/s. 
